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ABSTRACT
The objective of this research was to provide a vaccine for the control of 
brucellosis in reindeer, that allows serologic discrimination between vaccinated and 
infected animals. Three vaccines were tested: (1) Brucella suis 1, (2) B. suis 3, and (3) A 
rough mutant of the infective strain, B. suis 4. All were heat-killed and prepared in 
Freund’s incomplete adjuvant Each vaccine was administered to four animals. All 
vaccines stimulated the production of high levels of antibody in Rangifer that were 
maintained for the 483-day experiment. Significant delayed-type hypersensitivity 
reactions were seen in all vaccinated Rangifer. Both B. suis 1 and B. suis 3 vaccines 
allowed serologic discrimination between vaccinated and infected Rangifer. This was 
accomplished by means of an indirect ELISA (enzyme-linked immunosorbent assay). 
This test used whole cell B. melitensis and B. abortus as A and M-dominant antigens. 
Distinction could be made between vaccinated and infected reindeer based on a 
percentage difference in spectrophotometric absorbance values obtained with these 
antigens. The B. suis 3 vaccine provided the best discrimination. Eighty-nine percent of 
117 reindeer were correctly classified as either B. suis 3-vaccinated or B. suis 4-infected. 
Discrimination between vaccinated and infected reindeer was sufficient to allow 
assessment of the prevelance of brucellosis in vaccinated herds. In addition, the ELISA 
was more sensitive than standard agglutination tests in identifying reindeer with exposure 
to B. suis. The B. suis 3 vaccine was further evaluated in a challenge of 7 vaccinated 
reindeer. The vaccinated group consisted of 5 pregnant adults and 2 8-month-old female 
calves. These reindeer were challenged with 3.16 x 10^ colony forming units of B. suis 4 
at 63 days post-vaccination. Five pregnant adults and 1 female calf served as
iii
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experimental controls. B. suis 4 was isolated from 3 of 7 vaccinated reindeer (43%) at 
the time of necropsy. B. suis 4 was isolated from the aborted fetus of 1 of the infected 
vaccinates. Another infected vaccinate bore a healthy calf for which B. suis 4 could not 
be isolated. All control reindeer were infected and all 5 adults aborted. B. suis 4 was 
isolated from all 5 fetuses. The B. suis 3 vaccine provided significant protection against 
infection and abortion in reindeer challenged with B. suis 4.
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INTRODUCTION
Brucellosis is an infectious disease of mammals including humans, caused by 
bacteria of the genus Brucella. Most species of domestic animals are susceptible to 
infection by one or more species of Brucella. Distribution of the disease is world-wide 
(Thimm 1982).
BRUCELLOSIS IN REINDEER
Brucellosis due to Brucella suis biovar 4 is enzootic in populations of reindeer 
and caribou (Rangifer tarandus) throughout polar regions of the world (Meyer 1966). 
These animals are considered the primary host of B. suis 4. The bacteria causes 
reproductive losses through abortion and the birth of weak calves (Davidov 1961, 
Neiland et al. 1968). Additionally, the disease causes orchitis, epididymitis and sterility 
in males (Golosov and Zabrodin 1959), and arthritis and bursitis with accompanying 
lameness in both sexes (Davidov 1961, Nikolaevskii 1961, Orloff 1963).
TRANSMISSION
The primary mode of transmission of B. suis 4 in reindeer and caribou is believed 
to be via ingestion of aborted membranes and uterine discharges (Davidov 1961). 
Animals may become incidentally infected when feeding on a contaminated site.
Bacteria remain viable on the ground under arctic conditions for extended periods of time 
(Vaskevich 1973).
1
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2DIAGNOSIS
Antemortem diagnosis of brucellosis in Rangifer is based upon appearance of 
clinical signs and presence of Brucella-specific antibodies in the bloodstream. Abortion 
is the most common sign of the disease, but is difficult to observe in herded reindeer. 
Externally visible lesions are rare. Only 1-5% of reindeer in an infected herd may show 
obvious lesions (Cherchenko 1961). Serologic tests currently available for the diagnosis 
of brucellosis in reindeer accurately identify recently infected animals, but may fail to 
identify chronically infected ones (Golosov and Zabrodin 1959, Dieterich 1981).
Isolation of the bacterium from reindeer tissues is the only way to confirm a diagnosis. 
This step usually requires the slaughter and necrospy of reindeer.
ANTIBODY PREVALENCE OF BRUCELLOSIS IN ALASKAN REINDEER 
HERDS
Brucellosis is enzootic in most Alaskan reindeer herds. Antibody prevalence in 
reindeer herds ranges from <1% to >20% (Dieterich 1981). Similar prevalences have 
been reported by Russian researchers. Davidov (1974) reported that 11.1% of 1,756 
reindeer from Yakutia had serologic evidence of exposure to B. suis. Under such 
circumstances losses in herd productivity through abortion could be expected. Russian 
researchers have reported that abortion and barrenness range from 11% to 30% in 
Brucella-infected herds (Golosov and Zabrodin 1959).
CONTROL OF REINDEER BRUCELLOSIS
Control of brucellosis in Alaskan reindeer herds is sought for three reasons. First, 
herd productivity would be expected to improve where brucellosis levels are kept to a 
minimum. Under a suitable control program, reindeer herders would be able to 
maximize antler and meat harvests. Second, the risk of human infection to those working
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3within the reindeer industry would fall to negligible levels. Third, export markets for live 
reindeer would become available with the ability to assure brucellosis-free animals.
Brucellosis in domestic animals has been eradicated in many western countries 
through government-regulated test-and-slaughter programs in conjunction with the use of 
efficacious vaccines, where available (Alausa et al. 1986). Unfortunately, eradication of 
brucellosis in most herds of Alaskan reindeer is not feasible because reindeer are herded 
across exceptionally large areas of unfenced tundra.
Brucellosis in Alaskan herds of reindeer has been controlled with the use of a 
killed B. suis 4 vaccine. This vaccine provides protection against infection in laboratory 
trials (Dieterich et al. unpubl.). Results from field applications of this vaccine are also 
encouraging. Antibody prevalence has decreased from approximately 30% to < 5% in 
nonvaccinated "sentinel" animals in one vaccinated herd (Dieterich, pers. comm.).
The main disadvantage to this vaccine is that naturally-infected reindeer cannot 
be distinguished from vaccinated, noninfected animals. Serologic tests currendy 
available do not discriminate between the antibody response of vaccinated reindeer and 
infected reindeer. This has caused difficulties in: (1) Evaluating the prevalence of 
brucellosis in vaccinated herds, (2) Evaluating the efficacy of the vaccine as used under 
field conditions, and (3) Designating vaccinated reindeer as being free of actual infection. 
Currently, only nonvaccinated reindeer are selected for export from Brucella-enzootic 
areas because vaccinated, noninfected reindeer cannot be serologically distinguished 
from infected animals (Stahmann 1991). This is contrary to optimal control of the 
disease because reindeer originating from vaccinated herds would be less likely to harbor 
the organism than animals from nonvaccinated herds.
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4RESEARCH OBJECTIVES
The objective of this research was to develop a vaccine that: (1) Protects reindeer 
from infection with B. suis 4, and (2) Allows serologic discrimination between 
vaccinated and naturally infected animals. The initial phase of this research involved a 
trial of three vaccines. All three were expected to elicit an antibody response, which 
could be distinguished from that of an infected animal. The first two vaccines were 
based on biovars of Brucella infectious for swine, namely B. suis biovar 1 and B. suis 
biovar 3. B. suis 4 has been classified in the same species as these biovars because of 
similarities in biochemistry, metabolism and phage susceptibility (Meyer 1964).
B. suis 1 and B. suis 3 were chosen for the vaccine trial because they lack a form of O 
polysaccharide antigen, the M antigen, which is present in B. suis 4 (Alton et al. 1975, 
Wilson and Miles 1975). I hypothesized that reindeer vaccinated with these strains could 
be distinguished from those infected with B. suis 4 based on a differential response to this 
antigen. The third strain used in the trial was a rough B. suis 4 mutant, obtained from a 
laboratory at the National Animal Disease Center for the purposes of this study. I 
hypothesized that a vaccine based on this rough B. suis 4 mutant would produce an 
antibody response of low magnitude and short duration because this mutant lacks 
0  polysaccharide. By contrast, animals infected with B. suis 4 would be expected to 
show an antibody response of high magnitude and short duration.
RESEARCH DESIGN
These Brucella vaccines were initially tested in a small group of reindeer and 
caribou to compare induced humoral and cellular immunity. Humeral immunity was 
assessed for 18 months following vaccination by regular serologic testing. Cell-mediated 
responses were measured by a delayed-type hypersensitivity test with a B. suis 4 protein 
allergen given intra-dermally. This research is outlined in Chapter 1.
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5Simultaneously, an ELISA (enzyme-linked immunosorbent assay) procedure was 
developed to discriminate between infected reindeer and those vaccinated with either 
B. suis 1 or B. suis 3. This research is presented in Chapter 2. I used serum samples 
derived from the vaccinated reindeer and caribou in the 3-way vaccine trial as test sera.
Six months after the initiation of the 3-way vaccine trial, I chose the most 
promising of the three vaccines for further testing in a challenge experiment Criteria 
used for the selection of this vaccine were: (1) Humoral and cell-mediated immune 
responses of vaccinated Rangifer, and (2) Ability to discriminate between vaccinated and 
infected animals. The B. suis 3 vaccine was chosen for the challenge experiment I 
hypothesized that the B. suis 3 vaccine would produce sufficient immunity in reindeer to 
protect them against challenge with virulent B. suis 4. In this experiment, I challenged 
vaccinated and control reindeer with B. suis 4, and later compared them with regards to 
infection status and the occurrence of abortions. This research is presented in Chapter 3.
I also tested the B. suis 3 vaccine that was chosen for the challenge experiment in 
a free-ranging reindeer herd with an existing prevalence of serum antibody for brucellosis 
of < 1%. This biovar contains the A antigen but not the M antigen, whereas B. suis 4 
contains both antigens (Alton et al. 1975, Wilson and Miles 1932,1975). These antigens 
are chemically distinct O polysaccharide chains that form part of the smooth 
lipopolysaccharide complex (s-LPS) of the outer membrane of smooth Brucella species 
(Bundle et al. 1987, Cherwonogrodzky et al. 1987). Thus, ,8. suis 3-vaccinated reindeer 
should be discriminated from B. suis 4-infected reindeer based on the presence or 
absence of antibodies directed against the M polysaccharide antigen. Antibodies directed 
against this antigen might be detected by means of a specifically designed ELISA. In this 
manner, vaccinated reindeer could be differentiated from naturally infected animals. I
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6hypothesized that the B. suis vaccine would engender sufficient immunity in reindeer to 
protect against challenge with virulent B. suis 4.
The purpose of this field test was to provide a sufficient sample size of Brucella- 
free vaccinated reindeer with which to establish the sensitivity and specificity of the 
discriminatory ELISA. The ELISA results from field-vaccinated reindeer are presented 
in Chapter 2, along with the ELISA results from 11 reindeer vaccinated with B. suis 3 in 
the vaccine trials described previously.
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CHAPTER 1.
IMMUNOGENICITY OF BRUCELLA SUIS BIOVAR 1, BRUCELLA SUIS 
BIOVAR 3, AND ROUGH BRUCELLA SUIS BIOVAR 4 VACCINES IN
RANGIFER.
ABSTRACT
I tested 3 vaccines for prevention of brucellosis in Rangifer. (1) S. suis 1, (2)
B. suis 3, and (3) A rough mutant of B. suis 4, lacking smooth lipopolysaccharide. All 
were heat-killed and prepared in Freunds' incomplete adjuvant. I administered each 
vaccine to 4 animals. The humoral response elicited by the vaccines was assessed by 
regular serologic testing for 483 days. Cell-mediated responses were assessed by 
delayed-type hypersensitivity tests performed at 112 and 161 days post-vaccination. All 
vaccines stimulated the production of high levels of antibody in Rangifer that were 
maintained throughout the course of the experiment. Significant delayed-type 
hypersensitivity reactions were seen in all vaccinated Rangifer. I chose B. suis 3 vaccine 
for further testing and evaluation because of better discrimination.
INTRODUCTION
This chapter describes a trial of three vaccines for brucellosis in reindeer. All 
three vaccines were expected to produce an antibody response, which could be 
distinguished from that of an infected animal. Two vaccines were based on biovars of 
Brucella infectious for swine, B. suis biovar 1, and B. suis biovar 3. B. suis 1 and 
B. suis 3 were chosen for the vaccine trial because they contain the A antigen but not the 
M antigen, whereas B. suis 4 contains both antigens. Thus, I expected that reindeer
7
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8vaccinated with these strains could be distinguished from B. suis 4-infected reindeer 
based on a differential response to the M antigen. The third Brucella vaccine used in 
these trials was based on a rough B. suis 4 mutant, lacking major antigenic determinants 
normally present in B. suis 4 smooth-lipopolysaccharide (s-LPS). Here, I expected that 
vaccinated reindeer would show a weak and temporary antibody response as measured by 
standard serologic tests and enzyme-linked immunosorbent assay (ELISA), and could be 
distinguished from infected animals on this basis. The three vaccines were evaluated on 
the basis of ability to induce humoral and cell-mediated responses to Brucella in reindeer, 
and also on the degree of discriminadon between vaccinated and infected reindeer.
The objective of this research was to provide criteria on which to select one of the 
three vaccines for further testing and evaluation. Criteria used for selection were based 
on outcomes from tests of the following null hypotheses: (1) B. suis 3 and B. suis 1 
vaccines produce an antibody response in Rangifer that is similar in duration and 
magnitude, (2) Rough B. suis 4 vaccine produces an antibody response in Rangifer which 
is weak and transient, and (3) B. suis 3, B. suis 1, and rough B. suis 4 vaccines produce 
cell-mediated responses in Rangifer that are equivalent.
METHODS
Three B. suis strains were selected for evaluation as vaccines. B. suis 1330 is a 
typical biovar 1, whereas B. suis 636 is a typical biovar 3 isolated from swine and shown 
to be pathogenic for this species (Deyoe 1967). B. suis RAS is a laboratory-induced 
rough mutant of a B. suis 4 originally isolated from a Seward Peninsula reindeer (LAB 
2579). The National Animal Disease Center, located in Ames, Iowa, provided species 
strains and confirmed strain designations by standard typing procedures (Alton et al. 
1975). The rough mutant was typical of rough B. suis organisms in colony morphology, 
dye-exclusion characteristics and nonpathogenicity for guinea-pigs, but uncharacteristic
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diluted 1:200 with A monospecific serum, and exhibited incomplete agglutination when 
diluted 1:200 with M monospecific serum, and 1:400 with anti-rough B. suis serum.
The procedure used to prepare the 3 vaccines was identical to that used for the 
B. suis 4 vaccine, which currently is in use in Alaskan reindeer herds (Chapter 3). 
Experimental animals included groups of 3 yearling male reindeer, 3 yearling female 
reindeer, 3 yearling female caribou and 3 adult female caribou. These animals were 
housed at the Large Animal Research Station, University of Alaska Fairbanks. Vaccine 
treatments were allocated randomly within each group, controlling for differences in 
immune response relating to age, sex, and subspecies of Rangifer. Animals were 
vaccinated sub-cutaneously in the left mid-cervical area with 2 ml of vaccine containing 
approximately 10 mg cells per cubic weight. The experimental protocol used in this 
study was approved by an independent animal welfare committee at the University of 
Alaska Fairbanks.
The hypothesis that the B. suis 1 and B. suis 3 vaccines produce a humoral 
response in Rangifer, which was equal in duration and magnitude, was tested by 
sequential sampling and serologic testing of Rangifer treated with these vaccines. I 
sampled animals every week until antibody levels had peaked. After this time, I 
collected samples every 2 weeks. Sampling of Rangifer beyond 175 days post­
vaccination was less intensive; animals were sampled every 30-60 days until day 483.
Serologic tests employed were standard plate (SP), buffered Brucella antigen 
(BBA), rivanol (Riv) and A antigen-based enzyme-linked immunosorbent assay 
(ELISA). Standard procedures of the US Department of Agriculture (U.S. Department of 
Agriculture not dated, b, c) were used for the SP, BBA, and Riv tests. The ELISA 
procedure was an indirect assay developed by Douglas et al. (1984) and modified for use
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in reindeer (Chapter 2). An animal was considered positive if: (1) Agglutination 
occurred at a dilution of 1:25 on the SP, (2) Agglutination occurred on the BBA, (3) 
Incomplete agglutination occurred at a dilution of 1:25 on the Rivanol, and an optical 
density of 0.30 units was read on the ELISA.
Antibody curves based on geometric means were generated from the SP, Riv, and 
ELISA results of B. suis 1 and B. suis 3-vaccinated Rangifer and compared by fitting 
multiple regression equations (Zar 1984). Regression equations used to model the 
decline in SP and Riv titers after vaccination are modifications of a half-normal 
distribution: Y = ae^x, where Y = log of antibody titers, e = base of the natural 
logarithm, and a, b = regression coefficients. Weighted fifth-order polynomial 
regressions were used to model the antibody response of vaccinated reindeer as measured 
by ELISA; a spline curve-fitting procedure was used to generate the figures. Partial F- 
Tests were used as the criterion for including an additional term in the regression 
equation (Zar 1984). I compared BBA test results from vaccine treatment groups using 
the Friedman two-way test (Zar 1984).
The second hypothesis, that the rough B. suis 4 vaccine would produce a weak 
and transient antibody response, was similarly tested by sequential serologic testing of 
Rangifer treated with this vaccine. Regressions (previously described) were fitted to 
geometric means from SP, Riv, and ELISA tests. These regressions were compared with 
regressions from Rangifer treated with B. suis 1 and B. suis 3 vaccines.
The third hypothesis, that the three vaccines would produce equivalent cell- 
mediated responses to B. suis 4 in vaccinated Rangifer, was tested by assessing the 
allergic reactions of vaccinated Rangifer to a Brucella-protein allergen injected 
intradermally. The protein allergen was prepared at the National Animal Disease Center, 
Ames, Iowa, from cultures of a rough mutant of B. suis 4 that was laboratory-induced.
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The procedure employed results in a product with no detectable lipopolysaccharide 
(Bhongbhibhat et al. 1970, Jones etal. 1973).
I undertook delayed-type hypersensitivity trials with this protein allergen at 112 
and 161 days post-vaccination. In the first trial, lyophilyzed allergen was reconstituted at 
a concentration of 500 g/ml. A 0.1 ml aliquot of this solution was injected intradermally 
in the right-mid cervical skin of vaccinated Rangifer. Skin-fold thickness was measured 
with calipers prior to injection. For this procedure, skin was grasped between thumb and 
forefinger and calipers were placed over the doubled skin. I measured test sites again at 
24,48 and 72 h after injection. In addition, I examined skin thicknesses at 6 h post­
injection to verify that no immediate-type hypersensitivity reactions had been caused by 
injection of the allergen. Change in skin thickness was used to evaluate the strength of 
the resultant delayed-type hypersensitivity reactions. The Freidman 2-way test was used 
to examine differences in skin thickness between vaccine treatments.
I used a similar procedure for allergic testing in the second trial undertaken at 161 
days post-vaccination. Rangifer vaccinated with B. suis 1 and B. suis 3 were tested, 
along with 2 animals with no previous exposure to B. suis. In this trial, skin thickness 
was examined at 6 and 48 h. Biopsies were taken at 48 h from skin at test sites, and from 
normal skin distant to test sites. Lidocaine was injected sub-cutaneously to anesthetize 
biopsy sites in vaccinated Rangifer. This local anesthetic was placed approximately 10 
cm away from test sites in an L-shaped block to avoid causing edema in the test area. An 
alternative local anesthetic, a skin-freeze spray*, was used in control reindeer. The 
biopsy site was closed with the use of a skin stapler. Biopsy tissues were fixed in 10% 
buffered formalin, sectioned, stained with hematoxylin and eosin, and examined 
microscopically. Delayed-type hypersensitivity reactions were assessed on the following
1 Schuco, Div. A.C.I., Carle Place, NY 11514.
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criteria: (1) Presence of edema, and (2) Depth of perivascular cuffing by mononuclear 
cells in the venular plexuses, venules, and small veins of the papillary dermis and the 
reticular dermis. The degree of cuffing was judged to be normal, mild, moderate or 
severe and ranked on a Likert scale. The Mann-Whitney U- test was used to examine 
differences in perivascular cuffing between vaccine treatment groups. Fisher's exact test 
was used to compare the incidence in edema in the two vaccine groups (Zar 1984).
RESULTS
A significant difference occurred among regression lines modeling the decaying 
serologic response of B. suis 1 and B. suis 3-vaccinated reindeer as measured by SP (F = 
9.93; 3,26 df; P < 0.001), Riv (F = 11.41; 3,26 df; P < 0.001), and ELISA (F = 4.34; 6,38 
df; P < 0.005) tests (Figures 1.1,1.2, and 1.3). Both vaccines elicited production of 
similarly high levels of antibody. The B. suis 1 vaccine, however, produced a slightly 
longer duration antibody response as measured by SP and Riv tests. Conversely, the titer 
was greater with the B. suis 3 vaccine as measured in the ELISA. There was no 
significant difference in the serologic response of reindeer to these vaccines as measured 
by the BBA test Q& = 0 ,P  = 1.0), which gives a categorical result (Table 1.1). The 
B. suis 1 and 5. suis 3 vaccines did not produce antibody responses that were equivalent 
in duration and magnitude.
The rough B. suis 4 vaccine elicited production of high and long-lasting antibody 
levels. Serologic test results (titers) were generally lower than titers generated by the 
other vaccines. Regressions modeling the antibody response to rough B. suis 4 vaccine 
over time differed significantly from those produced by reindeer vaccinated with 
B. suis 1 (SP; F = 13.42; 3,26 df; P < 0.001; Riv; F = 12.04; 3,26 df; P < 0.001) and 
B. suis 3 (SP; F = 13.74; 3,26 d f;P <  0.001; Riv; F = 12.20; 3,26 df; P < 0.001; ELISA;
F = 7.38; 6,38 df; P < 0.001) (Figures 1.1,1.2, and 1.3). Polynomial regressions
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TABLE 1.1.
Buffered Brucella antigen test results for Rangifer vaccinated with B. suis 1, B. suis 3 and 
rough B. suis 4. Numbers of positive and negative test results in series of samples taken 
from each animal are presented.
B. SUIS 1 B. SUIS 3 B. SUIS 4
ANIMAL POS1 NEG2 POS NEG POS NEG
Yearling
male 20 1 21 0 21 0
reindeer
Adult
female 23 0 22 1 14 0
caribou
Yearling
female 23 0 23 0 15 8
caribou
Yearling
female 22 0 22 0 22 0
reindeer
TOTALS 88 1 88 1 72 8
* Positive test result is visible agglutination.
2 Negative test result is lack of visible agglutination.
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FIGURE 1.1.
Standard plate test results for three groups of 4 Rangifer vaccinated with B. suis 1, 
B. suis 3, or rough B. suis 4  vaccines.
Y (B. suis 1) = 2.840 x e*0-00181^  r2 = 0.88
Y (B. suis 3) = 2.814 x e '0-00176^  r2 = 0.88
Y (B. suis 4) = 3.281 x e-°003150X r2 = 0.72
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FIGURE L2.
Rivanol test results for three groups of 4 Rangifer vaccinated with B. suis 1, B. suis 3, or 
rough B. suis 4 vaccines.
Y (B. suis 1) = 2.369 x e-a001960X r2 = 0.50
Y (B. suis 3) = 2.662 x e '0-00042^  r2 = 0.84
Y (B. suis 4) = 3.129 x e '0-00328^  r2 = 0.69
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FIGURE 1.3.
Spectrophotometric absorbance values for three groups of 4 Rangifer spp. vaccinated with B. suis 1,
B. suis 3 or rough B. suis 4 as measured by ELISA.
Y (B suis 1) = 0.229 + (O ^lx lO ’^X - (0.266xl0’3)X2 + (0.128xl0’5)X3 - (0.277xl0’8)X4 + (0.218x10’ 
H )X5.
r2 = 0.94
Y (B.suis 3) = 0.365 + (0.254xl0’1)X - (0.264xl0’3)X2 + (0.123xlO’5)X3 - (0.260xl0’8)X4 + (0.201x10’ 
U )X5.
r2 = 0.88
Y (B. suis 4) = 0.183 + (O ^ x lO ’^X - (0.203x10’3)X2 + (0.811xl0’6)X3 - (0.152xl0*8)X4 + (0.108x10’ 
U )X5.
r2 = 0.97
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modeling ELISA results from B. suis 1 and rough B. suis 4-vaccinated reindeer were not 
significantly different (F = 2.13; 6,38 df; P > 0.2). BBA test results from B. suis 4- 
vaccinates did not differ significantly from those of B. suis 1 and B. suis 3-vaccinated 
Rangifer(X2 = 0,P =  1.0), (Table 1.1).
All three vaccines induced good cell-mediated immunity in Rangifer as evidenced 
by marked delayed-type hypersensitivity reactions to Brucella protein allergen. Changes 
in skin thickness (X2 (112 = 1.14, P > 0.56; Z  (161 = -0.15, P > 0.88) and
cellular changes resulting from allergen injection ( Z  (e£jema) = 0, P = 1; Z (Cuffmg) = -
0.61, P > 0.54) did not differ significandy between vaccine treatments. In the first 
allergic test, performed 112 days post-vaccination, the greatest changes in skin thickness 
were seen in B. suis 1-vaccinated reindeer (Table 1.2, Figure 1.4). Changes in skin 
thicknesses measured 48 and 72 h post-injection ranged from 0.9 to 10.5 mm in 
individual Rangifer. Measurements of skin thickness recorded at 24 h differed 
significantly from those taken later (X2 = 12.2, P < 0.002).
In the second allergic test, changes in skin thickness at 48 h ranged from 0.5 mm 
to 4.0 mm (Table 1.3, Figure 1.5). All skin sections from Rangifer showed edema, and 
distinct perivascular accumulations of lymphocytes and macrophages in superficial and 
deep dermal layers. These results confirm the presence of delayed-type hypersensitivity 
reactions (Table 1.4).
Vaccinated animals maintained a differential response to A and M antigens as 
measured in ELISA throughout 483 days of tesdng (Figure 1.6). In B. suis 3 vaccinates, 
this difference remained > 20%. This contrasts to results from rough B. suis 4-vaccinates 
(Figure 1.6) where percentage differences fell to levels approximating 0 at 100 days post­
vaccination. Regression equations modeling declines in percentage differences were
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TABLE 1.2.
Change in skin thickness at three time periods following injection of Brucella protein 
allergen in Rangifer 112 days post-vaccination with B. suis 1, B. suis 3 and rough 
B. suis 4 vaccines.
VACCINE ANIMAL CHANGE IN SKIN THICKNESS (mm) 
24 h 48 h 72 h
B. SUIS 1 AFCj
YFC:"
YFR3,
YMR4
1.5
2.0
7.0
2.0
3.5
3.5
9.5
3.5
3.0
3.5
10.5
4.0
MEAN
SD5
3.1
2.6
5.0
3.0
5.3
3.5
B. SUIS 3 AFC
YFC
YFR
YMR
1.5 
3.0
3.5
2.5
2.0
6.0
5.0
2.5
1.5
4.5 
6.0
2.5
MEAN
SD
2.6
0.9
3.9
1.9
3.6
2.0
B. SUIS 4 AFC
YFC
YFR
YMR
4.5 
3.0
2.5
4.5
6.5
2.5
5.0
5.0
5.5
3.5 
5.0
4.5
MEAN
SD
3.6
1.0
4.8
1.7
4.6
0.9
* Adult female caribou 
" Yearling female caribou 
^ Yearling female reindeer
4 Yearling male reindeer
5 Standard deviation
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FIGURE 1.4.
Change in skin thickness (mm) in three groups of 4 Rangifer injected with B. suis 4 
protein allergen 112 days after vaccination with B. suis 1, B. suis 3, and rough B. suis 4. 
Skin thickness was measured at 24,48 and 72 hours after intradermal injection. Means 
±1 standard error are presented.
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TABLE 1.3.
Change in skin thickness 48 h following injection of Brucella protein allergen in 
Rangifer 161 days post-vaccination with B. suis 1 and B. suis 3 vaccines.
VACCINE ANIMAL CHANGE IN SKIN THICKNESS (mm)
B.SUIS 1 AFC1 1.0
YFC2 2.5
YFR3 2.5
YMR4 3.5
MEAN 2.4
SD5 1.0
B. SUIS 3 AFC 0.5
YFC 4.0
YFR 2.5
YMR 3.0
MEAN 2.5
SD 1.5
* Adult female caribou
j: Yearling female caribou 
■" Yearling female reindeer
* Yearling male reindeer 
5 Standard deviation
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FIGURE 1.5.
Change in skin thickness (mm) in two groups of 4 Rangifer injected with B. suis 4 protein 
allergen 161 days after vaccination with S. suis 1 andfi. suis 3. Skin thickness was 
measured at 48 hours after intradermal injection. Means +1 standard error are presented.
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TABLE 1.4.
Cellular changes indicative of delayed-type hypersensitivity in skin biopsies taken from 
Rangifer at 48 h after injection of Brucella protein allergen. Biopsies were taken from 
normal skin in addition to skin at the test site and evaluated for die presence or absence 
of edema and depth of perivascular cuffing by inflammatory cells. Biopsy results from 
B. suis 1 and#, suis 3-vaccinated Rangifer tested 161 days post-vaccination are 
presented, along with results from control animals.
VACCINE ANIMAL SKIN TYPE EDEMA CUFFING
B. SUIS 1 AFC1 NORMAL NORMAL
TEST SLIGHT MILD
YFC2 NORMAL MILD
TEST + SEVERE
YFR3 NORMAL NORMAL
TEST + MODERATE
YMR4 NORMAL _ NORMAL
TEST + SEVERE
B. SUIS 3 AFC NORMAL NORMAL
TEST + MILD
YFC NORMAL SLIGHT MILD
TEST + MODERATE
YFR NORMAL NORMAL
TEST + SEVERE
YMR NORMAL _ NORMAL
TEST + MILD
CONTROL YFR NORMAL NORMAL
TEST SLIGHT MILD
YFR NORMAL _ NORMAL
TEST - NORMAL
* Adult female caribou
2 Yearling female caribou
3 Yearling female reindeer
4 Yearling male reindeer
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DAYS
FIGURE 1.6. Percentage differences in ELISA spectrophotometric absorbance values obtained on A and 
M-dominant antigens [(A - M)/A x 100)] for three groups of 4 Rangifer vaccinated with B. suis 1 (a),
B. suis 3 (b), and rough B. suis 4 (c) vaccines. Rangifer were sampled sequentially for 483 days after 
vaccination. Means ±1 standard error, and non-linear regression are presented.
Y (B. suis 1) = 75.866 x e-0 005740X f l  = o n
Y (fl. suis 3) = 71.531 x e-°004416X r2 = 0.89
Y (fl. suis 4) = 89.488 x e- ° 0214I5x r2 = 0.93
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significant among vaccine treatment groups: (a) B. suis 1 with rough B. suis 4 (F = 
138.38; 3,40 df; P < 0.001); (b) B. suis 1 with B. suis 3 (F= 17.16; 3,40 df; P < 0.001) 
(Fig. 1.6); and (c) B. suis 3 with rough B. suis 4 (F= 167.57; 3,40 df; P < 0.001) (Fig. 
1.6). The B. suis 3 vaccine provided a greater differential response to A and M antigens 
than did the B. suis 1 vaccine. Contrary to expectations, the rough B. suis 4 vaccine 
produced an antibody response of long duration and high magnitude.
DISCUSSION
All vaccinated Rangifer produced antibody as evidenced by high serologic titers 
in SP, Riv, BBA and ELISA tests. This result was desirable in B. suis 1 and B, suis 3 
vaccinates, but not in Rangifer vaccinated with rough B. suis 4. There was some 
variation in the humoral responses of Rangifer treated with the three vaccines. Titers as 
measured by Riv rose most quickly in B. suis 3-vaccinates and persisted longest in 
B. suis 1-vaccinates. Titers measured using SP rose most quickly in B. suis 1 and 
B. suis 3-vaccinates; and titers as determined by ELISA were slightly greater in B. suis 3- 
vaccinates. Consequently, I reject the first hypothesis that the B. suis 1 and B. suis 3- 
vaccines would produce an antibody response that was similar in magnitude and 
duration.
Variation in serologic test results between treatments may be an effect of 
experimental design. Nonetheless, this variation also may be attributed to a differential 
response in the production of different antibody types between individual Rangifer. Only 
four Rangifer were used per treatment. Therefore, natural variability of immune response 
between members of the group could alter geometric means. Research has shown that 
reindeer, which are exposed to Brucella under identical conditions, produce variable 
humoral responses (Dieterich, pers. comm.). Variation in titers between tests can be 
ascribed to the presence of different classes of immunoglobulin in Rangifer sera. In
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cattle, the SP test detects principally IgM and IgG2 , the buffered Brucella antigen test 
detects primarily IgGj and IgG2 , the Riv test detects primarily IgG j (Tizard 1987), and 
the ELISA is specific for reindeer IgG (Chapter 2).
Results from agglutination tests were more variable than results from ELISA. 
Agglutination tests present a crude system for the quantification of antibody; the observer 
visually inspects dilutions of serum in an antigen mixture for the presence of antibody- 
antigen complexes that have agglutinated (U.S. Department of Agriculture not dated, b, 
c). Agglutination is secondary to antigen-antibody complex formation, and assays 
employing this method of antibody quantization are termed a secondary-binding assays. 
The ELISA is a primary-binding assay that measures antigen-antibody interaction 
direcdy. Thus the higher variability of results in agglutination tests as compared to those 
from ELISA was not unexpected.
Rangifer vaccinated with rough B. suis 4 produced high levels of antibody as 
measured by all tests. Consequently, I reject the second hypothesis. Rough strains of 
Brucella lack polysaccharide normally present in s-LPS (Moreno et al. 1979). The 
polysaccharide component of LPS is important in eliciting antibody formation in exposed 
animals (Diaz et al. 1968). Indeed, antibodies detected in standard agglutination tests are 
mostly specific for O polysaccharide (Diaz et al. 1968, Schurig et al. 1981). The rough 
B. suis 4 strain used in this experiment is likely to have contained significant amounts of 
O polysaccharide because it elicited the production of high levels of antibody in Rangifer 
as measured in agglutination tests. This is not unusual for rough strains of Brucella. 
Degrees of "roughness" (variable coating of s-LPS) occur in dissociated cultures 
(Huddleson 1943), and specific rough strains possess small amounts of low molecular- 
weight polysaccharide (Meikle et al. 1989). In addition, this rough mutant was atypical 
of rough B. suis organisms because agglutination occurred with serum monospecific for
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A and M polysaccharide. This observation lends additional support to the conclusion that 
the rough B. suis 4 contained appreciable amounts of polysaccharide.
Rough strains of Brucella, which have been used to control brucellosis in 
domestic animals, do not elicit the production of long-lasting levels of measurable 
antibody (Alton et al. 1975). For example, domestic cattle vaccinated with B. abortus 
strain 45/20 produce low, transient levels of antibody. Killed B. abortus strain 45/20 has 
been tested in reindeer for the prevention of brucellosis (Dieterich et al. 1981). This 
vaccine did not induce high antibody levels in reindeer until these animals were later 
challenged with virulent B. suis 4 (Chapter 2), producing an anamnestic or secondary 
antibody response. The rough mutant of B. suis 4 used in this experiment was 
inappropriate for use in a vaccine. The production of a stable rough mutant completely 
lacking O polysaccharide, however, could provide excellent protection from brucellosis 
without the persistence of serologic titers (Schurig et al. 1991).
All three vaccines induced good cell-mediated immunity in Rangifer as evidenced 
by marked delayed-type hypersensitivity reactions to B. suis protein allergen. The third 
hypothesis is therefore supported. The use of allergic tests for brucellosis diagnosis in 
Rangifer has not been reported previously. Similar techniques have been employed 
successfully in brucellosis diagnosis in cattle, sheep, goats and pigs (Fensterbank 1985, 
Nicoletti and Winter 1990, Nicoletti 1983/1984). The protein allergen appears to have 
been free of LPS. No rise in serologic titers was seen following administration of the 
allergen, and no Arthrus-type (immediate hypersensitivity) reactions were noted. This 
test may be useful in identifying seronegative reindeer calves that are carriers for 
brucellosis. The allergic test has been reported to diagnose brucellosis in calves bora to 
infected cattle (Bercovich et al. 1990).
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The antibody response to A and M antigens differed most significantly in 
Rangifer vaccinated with B. suis 3. For this reason, and because of greater biochemical 
similarities with B. suis 4 (Alton et al. 1975), the B. suis 3 vaccine was chosen for further 
evaluation and testing.
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CHAPTER 2.
ENZYME-LINKED IMMUNOSORBENT ASSAY TO DISCRIMINATE 
BETWEEN BRUCELLA SUIS BIOVAR 4-INFECTED AND BRUCELLA SUIS 
BIOVAR 3-VACCINATED REINDEER.
ABSTRACT
Brucella suis biovar 4 is the causative agent of brucellosis in herds of Alaskan 
reindeer. Control of the disease has been based on the use of a killed B. suis 4 vaccine. 
Infected reindeer in vaccinated herds cannot be distinguished from vaccinated, 
noninfected animals by means of serologic tests currently available. A Brucella suis 
biovar 3 vaccine was tested that would allow serologic discrimination between 
vaccinated and infected reindeer based on a differential response to A and M 
polysaccharide antigens. An indirect ELISA (enzyme-linked immunosorbent assay) was 
developed using whole cell B. melitensis and B. abortus as A and M-dominant antigens. 
Epitopes shared by both A and M antigens were blocked with a monoclonal antibody, C-
1. The ELISA is more sensitive than standard agglutination tests in identifying reindeer 
with exposure to B. suis. Distinction could be made between vaccinated and infected 
reindeer based on a percentage difference in spectrophotometric absorbance values 
obtained on A and M-dominant antigens. Percent difference in A and M-specific 
antibody response diminished with time in vaccinated reindeer. Nevertheless, the 
indirect ELISA classified 89% of 117 reindeer correctly as either vaccinated or infected. 
Discrimination between B. suis 3-vaccinated and B. suis 4-infected reindeer is sufficient 
to allow assessment of brucellosis prevalence in vaccinated herds.
28
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INTRODUCTION
Brucellosis due to Brucella suis biovar 4 is enzootic in many herds of reindeer 
and caribou throughout the world (Meyer 1966). The disease is one of high morbidity 
and low mortality. The primary effects of the disease are reproductive loss from abortion 
in females and sterility in males (Golosov and Zabrodin 1959, Davidov 1961). In 
addition, infected reindeer frequently develop bursitis or arthritis with associated 
lameness (Davidov 1961, Nikolaevskii 1961, Dieterich 1981).
Most reindeer herds in Alaska are kept on unfenced ranges of up to 0.5 million 
hectares of mountainous tundra. Under such conditions, eradication of brucellosis with a 
test-and-slaughter program is not feasible. Instead, research efforts have been directed at 
producing a safe and efficacious vaccine that would control the disease in infected herds. 
A killed B. suis 4 vaccine has been tested in reindeer and provides an excellent level of 
protection (Dieterich et al. unpubl.). This vaccine is presently in use in most Alaskan 
herds of reindeer.
The main disadvantage to the use of this vaccine is that infected reindeer in 
vaccinated herds cannot be distinguished from vaccinated, noninfected animals. Visible 
brucellosis lesions only occur in 1-5% of reindeer in infected herds (Cherchenko 1961, 
Zabrodin et al. 1980). Serologic tests currently available do not discriminate between the 
antibody response of vaccinated and infected reindeer.
A killed B. suis biovar 3 vaccine was tested in reindeer. This vaccine might allow 
serologic discrimination between vaccinated and infected reindeer based on a differential 
response to the immunodominant A and M antigens of B. suis. These antigens are 
chemically distinct O polysaccharide chains that form part of the smooth 
lipopolysaccharide complex (s-LPS) of the outer membrane of smooth Brucella species 
(Bundle et al. 1987, Cherwonogrodzky et al. 1987). Certain biovars of Brucella have a
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
30
predominance of the A polysaccharide antigen. Examples include B. abortus biovar 1, 
and B. suis biovars 1,2 and 3. Other biovars possess a predominance of M 
polysaccharide; examples include B. melitensis biovar 1 (Wilson and Miles 1932).
B. suis 4 shows an equal proportion of both A and M antigens (Alton et al. 1975, Wilson, 
and Miles 1975). Thus, B. suis 3-vaccinated reindeer should be discriminated from 
B. suis 4-infected reindeer based on the presence or absence of antibodies directed 
against the M polysaccharide antigen. An indirect enzyme-linked immunosorbent assay 
(ELISA) was developed to detect reindeer antibodies specific for both A and M antigens. 
In addition to providing a means of discrimination between vaccinated and infected 
reindeer, this test would be highly sensitive in detecting reindeer with exposure to 
Brucella.
I tested the following hypotheses: (1) The indirect ELISA based on A antigen 
discriminates between reindeer with no previous exposure to B. suis. and those that have 
been exposed (this prior exposure may be due to either vaccination with B. suis 3 vaccine 
or infection with B. suis 4, and (2) The ELISA will discriminate between B. suis 4- 
infected and B. suis 3-vaccinated reindeer based on a differential antibody response to the 
M antigen.
METHODS
Production of Immunoglobulin G-specific Rabbit Anti-reindeer Serum
Immunoglobulin G-specific rabbit anti-reindeer serum was produced for the 
purpose of detecting reindeer IgG in the indirect ELISA. Serum protein in 100 ml of 
reindeer serum was precipitated with 27g of ammonium sulfate. The solution was stirred 
at 4°C for 12 h, centrifuged and the resulting pellet resuspended with sonication in 10S 
TEAN buffer consisting of 0.05M Tris HC1,0.001M EDTA, 0.003M NaN3, and 0.2M
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NaCl. The sonicate was dialyzed in 10S TEAN buffer and desalted in Bio-Gel P-6DG^ 
to remove remaining ammonium sulfate. Serum IgG was purified from the solution with 
DEAE Affi-Gel Blue^. First, the solution was dialyzed against a starting buffer of 0.02M 
Tris-HCl, pH 8.0,0.028M NaCl, and 0.02% NaNg. The gel was washed in 10 bed 
volumes of starting buffer, transferred to a column and eluted with 3 bed volumes of 
starting buffer prior to applying the desalted serum protein solution. After applying the 
solution, the column was again eluted with 3 bed volumes of starting buffer. Eluted 
fractions were collected in a Gilson FC-80 Micro-FractionatoA Spectrophotometric 
absorbance values for the fractions were read at 280 nm. Fractions with an optical 
density reading of > 0.5 were saved and pooled. The eluted IgG was concentrated by 
suspending the solution in dialysis tubing in a vacuum flask at 4<’C, until an optical 
density of 2 was reached. Azide was removed from the solution by dialysis. IgG purity 
was checked by sodium dodecyl sufate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a procedure described by Laemmli (1970).
The IgG solution was emulsified in Freunds complete adjuvant^ in a 1:1 ratio, 
using a double-hubbed coupler and 2 Luer Lock syringes as described by Berlin and 
McKinney (1958). One milliliter of the resulting vaccine was injected into 6 adult Rex 
rabbits, with one-half given sub-cutaneously, and one-half given intramuscularly into the 
triceps femoris. The rabbits were re-inoculated 5 weeks later in the same manner. One 
week after the second inoculation, the rabbits were anesthetized with ketamine (35mg/kg) 
and xylazine (5mg/kg) and bled by cardiac puncture. The sera derived from these rabbits 
was examined in an ELISA against a commercially prepared rabbit anti-reindeer serum^
1 Biorad Laboratories, 220 Wright Ave. Richmond, CA 94804.
2 Biorad Laboratories, 220 Wright Ave. Richmond, CA 94804.
3 Gilson Medical Electronics, Inc., Box 27,3000 W Beltline Hwy, Middleton, W I53562.
4 Sigma Chemical Co., P.O. Box 14508, St. Louis, MO 63178.
5 Kirkegaard & Perry Laboratories Inc., Gaithersburg, MA.
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for anti-reindeer IgG activity. All experimental procedures using live animals were 
approved by an independent animal welfare committee at the University of Alaska 
Fairbanks (UAF).
ELISA procedure
An indirect ELISA procedure developed by Douglas et al. (1984) was modified 
for detection of antibodies directed against both A and M B. suis epitopes. M and A- 
dominant antigens used in this test were acetone-killed whole cell preparations of 
Brucella melitensis strain 16M and Brucella abortus strain 119-3, (provided by B.L. 
Deyoe, U.S. Department of Agriculture, Ames, Iowa). Suspensions of each antigen were 
prepared in 0.01M ammonium acetate carbonate coating buffer (pH 8.2) at a 
concentration corresponding to a spectrophotometric optical density (OD) of 0.05 at 420 
nm. Fifty microliters of antigen suspension was placed in wells of Immunolon 2 U 
plates^ and allowed to dry overnight in an incubator at 37°C. B. melitensis antigen was 
placed in the 1st, 2nd, 5th and 6th plate rows and B. abortus antigen was placed in the 
3rd, 4th, 7th and 8th rows. This arrangement allowed for duplicates of each reindeer 
sample to be tested on both antigens in a sample configuration as suggested by 
Stemshom et al. (1983).
Nonspecific protein binding was blocked by the addition of 10% powdered skim 
milk^ to the working buffer, a phosphate-buffered saline containing 0.1% Tween, of pH 
7.4. Common determinants of A and M epitopes were blocked by an incubation with a 
monoclonal antibody, C-l, developed by Douglas and Palmer (1988). Plates were 
incubated with 100 pi of C-l at a dilution of 1:1,000 at 37°C for 45 min prior to the 
addition of test sera from reindeer. One-hundred microliters of test semm diluted at 
1:5,000 were added to each well and incubated for 1 h. This was followed by a 1 h
6 Dynatech Laboratories, Inc., Alexandria, VA.
7 Carnation Co., Los Angeles, CA 90036.
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incubation with rabbit anti-reindeer IgG at a dilution of 1:20,000. Bound rabbit antibody 
was detected by a commercially prepared peroxidase conjugated IgG fraction goat anti­
rabbit IgG**, which was incubated for 45 min at a dilution of 1:8,000.
An ortho-phenylenediamine (OPD)^ chromogen was used to indicate bound 
conjugate. This was prepared as a 6 mg/ml solution in citrate buffer (pH 5.2) of which 
50 (il was added to each well. Plates were incubated for 15-20 min prior to termination 
of the peroxidase-chromogen reaction by the addition of 50 |il of 2.5 N sulfuric acid. 
Inter-plate variability was reduced with the use of a timing protocol that targeted 
consistent color development in positive control sera (Wright et al. 1985). Optical 
density (OD) of control sera obtained at 4 min and 414 nm were used to calculate the 
time of test termination. This "target" time was calculated by a micro-computer and 
ELISA program, where the computer was interfaced with a Titertek Multiscan ^  ELISA 
reader. The ELISA program used was "ELISA" version 1.1, written by W. Kelly, ADRI, 
Agriculture Canada (Cherwonogrodzky et al. 1990). The peroxidase-chromogen reaction 
was terminated by the addition of 2.5 N sulfuric acid, and color production was read at 
492 nm.
Each sample was tested in duplicate on both A and M antigens. Percent co­
variances were calculated for each duplicate. Where a significant difference occurred 
between duplicates on one or both antigens, the sample was re-tested.
8 Cappel Laboratories, Organon Teknika Corp., 1230 Wilson Dr., West Chester, PA 
19380
9 Sigma Chemical Co., P.O. Box 14508, St. Louis, MO 63178.
10 Row Laboratories, 7655 Old Springhouse Rd., McLean, VA 22102.
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Control Sera
Serum known to contain anti-B. suis antibody was derived from a reindeer that 
was challenged with 3 x 10^ CFU of B. suis 4. This serum is hereafter referred to as a 
positive control. B. suis 4 was isolated from this animal at necropsy. The control sample 
was taken 2 months post-challenge and produced agglutination: (1) On the buffered 
Brucella antigen (BBA) test, (2) At a serum dilution of 1:400 on the standard plate (SP) 
test, and (3) At a serum dilution of 1:400 on the Rivanol (Riv) test. This sample 
produced a reading of approximately 1.5 OD on both A and M antigens ELISA. Serum 
with no anti-B. suis antibody was taken from a reindeer with no previous exposure to 
Brucella, and is hereafter referred to as a negative control. Values of approximately 0.05 
OD were recorded on both ELISA antigens. Reindeer serum for a vaccine control was 
taken from an animal 2 months after vaccination with heat-killed Brucella suis biovar 3 
in Freunds incomplete adjuvant (ETA). This sample approximated 0.4 OD on A antigen 
ELISA and 0.7 OD on M antigen ELISA and produced agglutination: (1) On the 
buffered Brucella antigen (BBA) test, (2) At a serum dilution of 1:400 on the SP test, and 
(3) At a serum dilution of 1:400 on the Riv test.
Test Sera
A) Negative sera
Blood was collected from reindeer that had no possibility of exposure to B. suis 4. 
These animals had been housed at the Large Animal Research Station and reindeer 
holding facility at the UAF. Thirty sera were selected randomly from 150 possible 
samples.
B) Positive sera from infected reindeer
Thirty samples from infected reindeer were selected randomly from 80 possible 
samples. B. suis 4 had been isolated from all these animals. These animals represented
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both laboratory and field-infected reindeer, including 12 calves. The samples chosen 
were expected to represent both chronically and acutely infected reindeer.
Nineteen of 30 sera were from Seward-Peninsula reindeer with brucellosis lesions 
from which B. suis 4 was isolated. These lesions included swollen joints or associated 
bursa (42%), testicular abscesses (42%), necropurulent lymph nodes (10%), and vaginal 
discharges (5%). Abscesses and necropurulent brucellosis lesions traditionally have been 
regarded as chronic manifestations of brucellosis in reindeer (Nikolaevskii 1961, 
Zabrodin et al. 1980, Dieterich 1981). One of these infected reindeer showed no 
evidence of previous exposure based on agglutination tests.
Eleven additional samples were obtained from reindeer infected in laboratory 
vaccine trials. The reindeer had been sampled sequentially over 4 months following 
challenge. A sample for testing was selected randomly from each sequence. Two 1- 
month-old infected calves of challenged females also were tested. The 12 samples from 
these experimental reindeer were considered to be from recently infected animals.
C) Sera from vaccinated reindeer
Samples from vaccinated reindeer were derived from two sources. Eleven 
samples were taken from reindeer in vaccine-efficacy experiments (Chapters 1 and 3)
2 months after vaccination with a killed B. suis 3 vaccine.
Other samples from vaccinated reindeer were collected from members of a free- 
ranging herd. In November 1988,100 reindeer in the Shaktoolik reindeer herd were 
vaccinated with B. suis 3 vaccine. This herd of approximately 1,200 animals was 
considered relatively free of brucellosis. One-hundred reindeer in this herd had been 
tested in June 1988 by UAF researchers. No serologic evidence of exposure to B. suis 4 
was detected by means of BBA, SP or Riv. The range of the Shaktoolik herd overlapped 
with migratory routes of the Western Arctic caribou herd. This caribou herd showed an
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18% prevalence of serum antibodies of brucellosis during the years 1986-1989, based on 
samples taken from 44 animals (R. Zamke, pers. comm.) There were possibilities for 
transmission of brucellosis from infected migrating caribou to this "clean" herd, but no 
brucellosis lesions were observed.
The 100 animals vaccinated with B. suis 3 included 50 adult females, 25 6-month- 
old male calves, and 25 6-month-old female calves. These reindeer, and 16 additional 
control reindeer, were ear-tagged and bled at the time of vaccination in November 1988, 
and bled again in June 1989 (n = 76), November 1989 (n = 70) and June 1990 (n = 46). 
Thirty-three additional reindeer were bled in these successive handlings to monitor the 
background prevalence of brucellosis.
D) Serial samples from both vaccinated and challenged reindeer.
The normal course of antibody responses to A and M antigens in reindeer 
following vaccination or infection was further investigated by testing serial samples from 
11 reindeer used in vaccine-efficacy trials at UAF (Chapter 1, Chapter 3). Serial samples 
from 4 Rangifer, which were vaccinated with B. suis 3 and monitored for 18 months 
following vaccination, were tested with ELISA. Serum samples derived from 7 reindeer 
vaccinated with killed B. suis 3 vaccine, and 2 months later challenge with B. suis 4, also 
were tested. Three of the 7 vaccinates and 6 controls had become infected with B. suis 4 
following challenge. Sequential samples spanning the 6 months from the time of 
vaccination to necropsy were tested for all animals in each group.
Experimental Design
I tested the hypothesis that the A antigen-based ELISA discriminates between 
reindeer that previously have been exposed to B. suis, and those with no previous 
exposure, by comparing values of spectrophotometric absorbance obtained with samples 
from these two groups of animals. In this experiment, exposure to B. suis included
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vaccination with B. suis 3 or infection with B. suis 4. I tested 30 "negative" and 177 
"positive" samples on the A-antigen ELISA, where the "positive" group was composed 
of: (1) 30 samples from infected reindeer, (2) 11 samples from reindeer sampled 2 
months post-vaccination, and (3) 76 samples from reindeer sampled 7 months post­
vaccination. Discriminant function analysis (DFA) (Johnson and Wichem 1988) was 
used to classify negative and positive sera using values of spectrophotometric absorbance 
obtained on the A antigen. Prior probabilities used in the DFA were based on sample 
size. I also compared results from the A antigen-based ELISA with results from standard 
agglutination tests including the buffered Brucella antigen, standard plate, and Rivanol 
tests (U.S. Department of Agriculture not dated, b, c).
I hypothesized that the ELISA discriminates between B. suis 4-infected and 
B. suis 3-vaccinated reindeer based on a differential antibody response to the M antigen. 
This hypothesis was tested by comparing spectrophotometric absorbance values from 
vaccinated and infected reindeer obtained on the M antigen ELISA. DFA was used to 
classify 87 vaccinated reindeer sampled 2 and 7 months post-vaccination and 30 infected 
reindeer using M antigen ODs. The groups of reindeer vaccinated at 2 and 7 months 
were combined for this analysis to form a representative group of vaccinated animals 
with the largest possible sample size. Prior probabilities used in this analysis again were 
based on sample size.
I also assessed an alternative means of discrimination, based on the percentage 
difference in spectrophotometric absorbance values obtained on A and M antigens. DFA 
was used to classify 87 vaccinated reindeer sampled 2 and 7 months post-vaccination and 
sera from 30 infected reindeer using the calculated percentage difference [% difference = 
(A - M)/A x 100)], where A = OD readings from the A-antigen ELISA.
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Serial blood samples were obtained from reindeer after vaccination with B. suis 3 
or infection with B. suis 4. Sera were tested to evaluate the changes in A and M-specific 
antibody responses over time. Polynomial regressions (5th order) were fitted to 
geometric means for OD readings from ELISA based on both A and M antigens; curves 
were fit as in Chapter 1. Partial F-tests were used to determine the number of parameters 
in these equations (Zar 1984). Autocorrelations in regression analyses were minimized 
by the selection of an optimal sampling interval. Weighted regression analysis was used 
where samples were missing from a series. Mean weighting factors in a series were 
never < 94% of full weighting. Nonlinear regressions, modifications of a half-normal 
distribution (Y = ae*3*), were fitted to mean percentage differences as measured over 
time. Regression lines modeling A and M responses in vaccinated and control reindeer 
were compared using the procedure of Zar (1984). Similarly, comparisons were made 
between regression lines fitted to percentage differences in vaccinated reindeer that were 
infected with B. suis 4 and those that were not infected.
RESULTS
Serologic Determination of Nonexposed. Vaccinated, and Infected Reindeer
Reindeer that had not been exposed to B. suis 4 could be differentiated from 
vaccinated and infected reindeer based on values of spectrophotometric absorbance 
obtained in the A antigen-based ELISA. Both vaccinated and infected reindeer had a 
high level of antibody against this antigen as measured by the ELISA (Table 2.1). This is 
in contrast to data for unexposed animals, which showed negligible levels of antibody to 
the A antigen (Figure 2.1).
ELISA determinations for the vaccinated group was composed of samples taken 
from 11 reindeer sampled 2 months post-vaccination, and 76 reindeer sampled 7 months 
post-vaccination. No overlap occurred in A antigen OD readings between the "positive"
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TABLE 2.1.
Spectrophotometric absorbance values obtained on A and M-dominant antigens and 
percentage difference statistic [(A - M)/A x 100)] for 30 negative reindeer, 30 infected 
reindeer, and reindeer sampled at 2 ,7 ,12, and 19 months post-vaccination (P.V.) with 
S. suis 3 vaccine. Group sizes for the vaccinated reindeer were 11,76,70 and 46, 
respectively. Means, standard deviations and ranges are presented.
SAMPLE TYPE A MEAN SD RANGE
NEGATIVE 0.04 0.02 (0.01-0.09)
INFECTED 1.56 0.21 (1.14-2.00)
2 MO P.V. 1.42 0.70 (1.20-1.58)
7 MO P.V. 1.52 0.27 (0.92-2.18)
12 MO P.V. 1.21 0.17 (0.65-1.44)
19 MO P.V. 1.22 0.20 (0.62-1.65)
SAMPLE TYPE MMEAN SD RANGE
NEGATIVE 0.07 0.07 (0.02-0.37)
INFECTED 1.50 0.26 (0.77-2.00)
2 MO P.V. 0.61 0.32 (0.23-0.86)
7 MO P.V. 1.23 0.27 (0.58-1.78)
12 MO P.V. 1.04 0.20 (0.54-1.33)
19 MO P.V. 0.97 0.20 (0.33-1.36)
SAMPLE TYPE %DIFF MEAN SD RANGE
NEGATIVE NA
INFECTED 3.9 11.0 (-34.4-31.9)
2 MO P.V. 57.5 14.3 (37.9-80.7)
7 MO P.V. 19.6 9.6 ( 5.4-48.8)
12 MO P.V. 14.3 9.8 (-3.1-40.4)
19 MO P.V. 21.1 10.0 ( 1.7-64.0)
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NEGATIVE VACCINATED INFECTED
REINDEER REINDEER REINDEER
FIGURE 2.1.
ELISA optical density readings on A-dominant antigen. Means for three groups of 
negative, B. suis 3-vaccinated and infected reindeer are presented with bars representing 
+1 standard error. B. suis 3-vaccinated reindeer include 11 reindeer sampled 2 months 
after vaccination, and 76 reindeer sampled 7 months after vaccination.
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samples from vaccinated and infected reindeer and the "negative" samples from reindeer 
with no exposure to B, suis. All 147 samples taken from these 2 groups of positive and 
negative reindeer were classified correctly by DFA using OD readings from A antigen- 
based ELISA.
Criteria for differentiating reindeer that had been exposed to B. suis from those 
which had not were determined from the results of this analysis. Sample 
spectrophotometric absorbance values of < 0.15 OD were designated "negative," and 
sample OD readings of > 0.30 were designated "positive." Intermediate samples were 
designated as "doubtful."
Results of A antigen-based ELISA from these groups of negative and positive 
(vaccinated or infected) reindeer were compared with results from agglutination tests 
(Table 2.2). The ELISA was most sensitive, identifying all vaccinated and infected 
reindeer as "positives," whereas other agglutination tests did not. The sensitivity of the 
ELISA was 100% in this sampling, the BBA test was 97% sensitive, the SP test was 96% 
sensitive, and the Riv test, was 91% sensitive.
I expected that vaccinated reindeer would show negligible antibody activity. This 
expectation was not supported (Table 2.1). The reindeer sampled at 2 months post­
vaccination showed the lowest readings and greatest contrast to the infected group on the 
M antigen-based ELISA. The M antigen-based ELISA discriminated between vaccinated 
reindeer and infected reindeer (sampled at 2 and 7 months post-vaccination) with a 
specificity of 98% and a sensitivity of 30% using DFA.
A high level of discrimination between vaccinated and infected reindeer was 
accomplished with the calculation of a percentage difference in spectrophotometric 
absorbance values obtained on the A and M antigen-based ELISAs. I expected that the 
calculated percentage difference for infected reindeer would approximate 0, whereas
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TABLE22
Results of A-dominant antigen based ELISA as compared with buffered Brucella antigen 
(BBA), standard plate (SP), and rivanol (Riv) tests for groups of 30 negative reindeer, 30 
infected reindeer, and 87 reindeer vaccinated with killed B. suis 3 vaccine. The sensitivity 
of each test in identifying reindeer with exposure to Brucella is also given.
TEST RESULT NEG (30) VAC (87) INF (30) SENSITIVITY
BBA + 0 87 27 97%
- 30 0 3
SP + 0 86 26 96%
- 30 1 4
Riv + 0 82 25 91%
- 30 5 5
A-ELISA + 0 87 30 100%
30 0 0
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vaccinated reindeer would produce a much higher percentage difference. The mean 
percentage difference for infected reindeer was 3.9% (Table 2.1 and Figure 2.2), 
supporting the assumption that B. suis 4-infected reindeer would show equal antibody 
production against both A and M antigens. The mean percentage differences for reindeer 
sampled at 2 ,7 ,12, and 19 months post-vaccination were 57.5%, 19.6%, 14.3% and 
21.1%, respectively (Table 2.1 and Figure 2.2), supporting the assumption that there 
would be a much greater difference in vaccinated than in infected groups. There was a 
significant difference (P < 0.001) between the mean of the infected group and the means 
of these 4 vaccinated groups using the Mann-Whitney (7-test [Z = -4.8 (2 mo), -6.4 (7 
mo), -4.5 (12 mo), -6.1 (19 mo)]. Frequency distributions of percentage differences for 
vaccinated and infected reindeer are skewed, but distinct (Figure 2.3). DFA using rank- 
transformed data discriminated between vaccinated and infected reindeer with a 92% 
specificity (correctly classified negatives) and an 80% sensitivity (correctly classified 
positives). A total of 89% of vaccinated and infected reindeer were classified correctly 
by DFA based on rank-transformed percentage difference.
A simulation was performed to determine if increasing sample sizes would 
improve the percentage of reindeer correctly classified by DFA. A sample size of 30 for 
both vaccinated and infected groups resulted in a 74% correct classification using 
percentage difference as the only variable. Seventy-eight percent of reindeer were 
classified correctly with groups of 50, and 78% of the animals were classified correctly 
with groups of 75 in this simulation. These results indicate that a sample size of 50 to 75 
for the infected group of reindeer would have improved discrimination.
Time Series ELISA Results in Vaccinated and Infected Reindeer
The antibody response to the M antigen never reached the level of the response to 
the A antigen (Figure 2.4). Regression equations fitted to antibody responses to A and M
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FIGURE 22.
Percentage differences in spectrophotometric absorbance values obtained on A and M- 
dominant antigens [(A - M)/A x 100)] for infected reindeer, and reindeer sampled at 2,7, 
12, and 19 months post-vaccination with 5. suis 3 vaccine. Means for these groups are 
presented with bars representing +1 standard errors.
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% DIFFERENCE
FIGURE 23.
Frequency histogram of percentage differences in spectrophotometric absorbance values 
obtained on A and M-dominant antigens [(A - M)/A x 100)] for 87 B. suis 3-vaccinated 
and 30 B. suis 4-infected reindeer. B. suis 3-vaccinated reindeer include 11 reindeer 
sampled 2 months post-vaccination and 76 reindeer sampled 7 months post-vaccination.
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FIGURE 2.4.
Serologic response of 4 Rangifer to A and M-dominant antigens after vaccination with B. suis 3 vaccine. 
Reindeer were sampled sequentially for 18 months after vaccination. Results are presented as geometric 
means of A and M antigen ELISA spectrophotometric absorbance values obtained on A and M-dominant 
antigens along with weighted polynomial regressions.
Y (A antigen) = 0.456 + (O-SiexlO-^X - (0.326x10"3)X2 + (0.149xl0"5)X3 - 
(0.306xI0'8)X4 + (0.230xl0‘* *)X5.
r2 = 0.88
Y (M antigen) = 0.146 + (0.697xl0"2)X - (0.300xl0"5)X2 - (0.900xl0"7)X3 + (O ^lxK T^X 4 - 
(0.257x10"12)X5.
r2 = 0.98
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antigens were significantly different (F = 102.37, P < 0.001). Percentage difference in 
antibody responses to the A and M antigens in 4 Rangifer monitored for 483 days post­
vaccination showed a marked decline from 70% 28 days post-vaccination, to 16-41% 280 
days later (Figure 2.5). A percentage difference of approximately 20% was maintained 
even while titers decline.
The other sample series was obtained from 7 reindeer challenged with virulent 
B. suis 4 at 63 days post-vaccination. Three of these challenged reindeer subsequently 
became infected with B. suis 4 (Chapter 3). I expected that the percentage difference for 
vaccinated reindeer that were challenged but not infected would remain above the 20% 
level, whereas the percent difference for vaccinated reindeer that were later infected 
would fall to approximately 0%. The percentage difference results from vaccinated 
reindeer that were challenged (Figures 2.6 and 2.7) support this assumption. When 
measured at 175 days, percentage differences for uninfected reindeer were above the 
30% level in all but 1 animal, which was 12%. In contrast, percentage difference for 
vaccinated reindeer that became infected began to decline markedly at the time of 
challenge in 2 of 3 reindeer. Final samples taken from these 3 reindeer at 175 days post­
vaccination and 112 days post-challenge approximated a 10% difference. Regression 
equations tracking percentage differences in infected and noninfected vaccinates were 
significantly different (F = 22.64, P < 0.001).
The A antibody response curve differed significantly from the M antibody curve 
for all vaccinated reindeer, regardless of infection status [P < 0.001; F (infected 
vaccinates)— 53.61, F (uninfected vaccinates) = 36.08]. All vaccinated reindeer showed a 
strong antibody response to the A antigen within 14 days of vaccination, with percent 
differences ranging from 24-78%. This was followed by a slowly increasing antibody 
response to the M antigen. The A and M antibody responses in infected reindeer
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
48
DAYS
FIGURE 2.5. ■ a a \a
Percentage differences in spectrophotometric absorbance values obtained on A and M- 
dominant antigens [(A - M)/A x 100)] for 4 Rangifer sampled sequentially for 18 months 
after vaccination with B. suis 3 vaccine. Means ±1 standard error are presented.
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FIGURE 2.6.
Percentage differences in spectrophotometric absorbance values obtained on A and M- 
dominant antigens [(A - M)/A x 100)] for sequential samples obtained from 4 reindeer 
vaccinated with B. suis 3 vaccine and challenged 2 months later with virulent B. suis 4. 
Day 1 represents the day of vaccination. All four reindeer remained culture-negative for 
B. suis 4 following challenge. Means ±1 standard error and non-linear regression are 
presented.
Y = 73.412 xe-°-00636x r2 = 0.71
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DAYS
FIGURE 2.7.
Percentage differences in spectrophotometric absorbance values obtained on A and M- 
dominant antigens [(A - M)/A x 100)] for sequential samples obtained from 3 reindeer 
vaccinated with B. suis 3 vaccine and challenged 2 months later with virulent B. suis 4. 
Day 1 represents the day of vaccination. All three reindeer became infected with B. suis 4 
following challenge. Means +1 standard error and non-linear regression are presented.
Y = 144.206 x e-°-0l384X r2 = 0.92
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converged. Responses for Brucella-free reindeer remained distinct (Figures 2.8 and 2.9). 
This disparity was due to a difference in antibody responses to the M antigen following 
challenge (Figure 2.10). Regression equations tracking M antibody responses in the 2 
groups were significantly different, (F = 3.98, P < 0.02), indicating that vaccinated 
reindeer, which later become infected, can be differentiated from noninfected vaccinates 
on the basis of the percentage difference.
Sequential samples from the 6 unvaccinated reindeer in the B. suis 4 challenge 
experiment also were tested on ELISA to track the antibody responses to A and M 
antigens following infection. I expected that these reindeer would develop both A and 
M-specific antibody responses at an equal rate, and that the percentage differences would 
remain static at approximately 0. This expectation was not met by data from the 6 
nonvaccinated reindeer that were infected (Figures 2.11 and 2.12). Antibody response to 
the A antigen developed more rapidly than the response to the M antigen, creating a spike 
in percentage difference results shortly after challenge. This spike was as high as 50% in 
4 of 6 reindeer 3 weeks after challenge, but fell near 0 within 7 to 9 weeks following 
challenge in 5 of 6 reindeer.
One of 6 nonvaccinated reindeer lagged behind others in developing an antibody 
response to infection. Antibody levels peaked much later and at a lower level than in 
other animals infected at the time of challenge. This animal exhibited a delayed antibody 
response to the M antigen in relation to the A response. The percentage difference in 
antibody responses to these antigens only had fallen to 21% 13 weeks post-challenge.
The regression tracking the antibody response to the A antigen differed significantly from 
the regression for the antibody response to the M antigen in unvaccinated, infected 
reindeer (F = 20.58, P = 0.001).
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DAYS
FIGURE 2.8.
Serologic response of 4 reindeer to A and M-dominant antigens after vaccination with B. suis 3 vaccine and 
subsequent challenge with virulent B. suis 4 two months later. Reindeer were sampled sequentially for 6 
months from the date of vaccination (day 1). All four reindeer remained culture-negative for B. suis 4 
following challenge. Results are presented as geometric means of ELISA spectrophotometric absorbance 
values obtained on A and M-dominant antigens aiong with polynomial regressions.
Y (A antigen) = 0.107 + (0.582xl0'1)X - (0.105xl0-2)X2 + (0.954xl0'5)X3 - (0.428xl0-?)X4 + 
(0.756xl0-1(j)X5. 
r2 *  0.93
$  (M antigen) = 0.159 + (0.819xl0-2)X + (O.SSSxlO^JX2 - (0.237xl0-5)X3 + (0.193xl0’7)X4 - 
(0.528xl0'10)X5. 
r2 = 0.90
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DAYS
FIGURE 2.9.
Serologic response of 3 reindeer to A and M-dominant antigens after vaccination with B. suis 3 vaccine and 
subsequent challenge with virulent B. suis 4 two months later. Reindeer were sampled sequentially for 6 
months from the date of vaccination (day 1). All three reindeer became infected with B. suis 4 following 
challenge. Results are presented as geometric means of ELISA spectrophotometric absorbance values 
obtained on A and M-dominant antigens along with polynomial regressions.
Y (A antigen) = 0.388xl0'3 + (O ^x lO -^ X  - (0.110xl0*2)X2 + (0.836xl0'5)X3 - (0.235xl0’7)X4 + 
(0.852xl0-n )X5.
r2 * 0.97
Y (M antigen) = 0.117 + (0.470x10'2)X + (0.167xl0’3)X2 - (0.347xl0‘5)X3 + (0.286xl0'7)X4 - 
(0.784x10-10)X5.
r2 = 0.96
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
54
2.0 
1.8 
"g 1.6
1 1.4 
3  
> 1.2
1 1.0 
UJ 
5  0.8 
<
O0.6 
8  0.4
02
0.0
B¥
18 36
■ M
s
/ I
□ J r *
■ A ' '
□
B,/
'  /  s
CHALLENGE
I
■ CULTURE POSITIVE 
□ CULTURE NEGATIVE
54 72 90 108 126 144 162 180
DAYS
FIGURE 2.10.
Serologic response of 7 reindeer to M-dominant antigens after vaccination with B. suis 3 vaccine and 
subsequent challenge with virulent B. suis 4 two months later. Reindeer were sampled sequentially for 6 
months from the date of vaccination (day 1). Four reindeer remained culture-negative for B. suis 4 
following challenge, and three were infected. Results are presented as geometric means of ELISA 
spectrophotometric absorbance values obtained on M-dominant antigens along with polynomial 
regressions.
Y (culture-negatives) = 0.159 + (0.819xl0'2)X + (O.BSSxlO^X2 - 
(0.237x10-5)X3 + (0.193x10-7)X4 - (0.528xl0-1(^ X5.
r 2 = 0.90
Y (culture-positives) = 0.117 + (0.470x10'2)X + (0.167xl0*3)X2 - 
(0.347x10“5)X3 + (0.286x10"7)X4 - (0.784xlO-10)X5.
r2 = 0.96
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DAYS
FIGURE 2.11.
Percentage differences in spectrophotometric absorbance values obtained on A and M- 
dominant antigens [(A - M)/A x 100)] for sequential samples obtained from 6 reindeer 
challenged with virulent B. suis 4. All 6 reindeer became infected with B. suis 4 
following challenge. Means ±1 standard error are presented along with a weighted 
polynomial regression.
Y = 250.751 x e-°-02233x r2 = 0.92
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DAYS
FIGURE 2.12.
Serologic response of 6 reindeer to A and M-dominant antigens after vaccination with challenge with 
virulent B. suis 4. Reindeer were sampled sequentially for 4 months from the date of challenge. All 6 
reindeer became infected with B. suis 4 following challenge. Results are presented as geometric means of 
ELISA spectrophotometric absorbance values obtained on A and M-dominant antigens along with a 
weighted polynomial regression.
Y (A antigen) = 43.49 - 2.091 X + (0.379xl0-1)X2 - (0.324xl0'3)X3 +
(0.132x10'5)X4 - (0.210x10-8)X5.
1-2 = 0.99
Y (M antigen) = 33.21 - 1.529 X + (0.266x10'*)X2 - (0.219xl0‘3)X3 +
( O ^ x ^ X 4 - (0.133xl0'8)X5.
r2 = 0.99
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DISCUSSION
Use of ELISA for the Diagnosis of Brucellosis in Reindeer
The ELISA has a high degree of sensitivity and specificity in distinguishing 
between reindeer that have been exposed to Brucella and those with no previous 
exposure. This is true whether reindeer have been exposed by vaccination with B. suis 3 
or by infection with B. suis 4. All 147 reindeer were classified correctly as "negative" or 
"positive" using A antigen-based spectrophotometric absorbance values by DFA. 
Consequently, I accept the first research hypothesis.
All ELISAs were conducted in parallel with standard agglutination tests. These 
results, which are presented here and elsewhere (Chapter 1, Chapter 3), indicate that the 
IgG-specific ELISA is the most sensitive test. The ELISA detects B. suis-specific 
antibody as early as either SP or BBA tests.
Discrimination Between Vaccinated and Infected Reindeer
Discrimination between vaccinated and infected reindeer based on a differential 
antibody response to the M antigen was not possible using available techniques.
Reindeer vaccinated with B. suis 3 exhibited substantial M-specific antibody activity as 
measured in ELISA. Thus I reject the second hypothesis. B. suis 3 has been regarded as 
a typical A+M- serovar (Alton et al. 1975, Wilson and Miles 1975). Positive or negative 
signs indicate reactions with serum specific for A or M antigens. A recent study has 
shown that M polysaccharide constitutes a small fraction of the total O polysaccharide 
content of this biovar (Meikle et al. 1989), The high level of antibody against 
B. melitensis seen in reindeer vaccinated with B. suis 3 therefore is difficult to explain.
High OD readings obtained on the M antigen ELISA with sera from vaccinated 
reindeer could be explained by the binding of antibodies with specificities for antigens
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other than the M antigen. This is a likely explanation considering the complex structure 
of the outer membrane of smooth B. suis.
The outer membrane of gram-negative bacteria contains lipoprotein, porins, 
phospholipids, and lipopolysaccharides (LPS) (Martin and Hancock 1990). The s-LPS of 
smooth gram-negative species consists of an O polysaccharide attached via a core 
oligosaccharide to lipid A, that anchors the molecule to the outer membrane 
(Cherwonogrodzky et al. 1990). The 0  polysaccharide, which contains the major 
antigenic epitopes of the s-LPS molecule and of the cell (Diaz et al. 1968, 
Cherwonogrodzky et al. 1990), projects outwards from the outer membrane surface.
O polysaccharide on smooth Brucella spp. takes one of two forms: (1) An A antigen 
consisting of monomeric repeating units of 4,6-dideoxy-4-foramido-D-mannose with a 
1,2 linkages (Caroff et al. 1984b) or (2) M antigen, identical to A antigen except that an 
a 1,3 glycosidic linkage replaces the a 1,2 linkage every 5th residue (Bundle et al. 1987). 
Research by Bundle et al. (1989) indicates that A-specific epitopes are a  1,2-linked 
pentasaccharides or larger oligosaccharides and M-specific epitopes are a  1,3-linked 
disaccharides with adjacent a 1,2 linkages. Epitopes consisting of linear portions of a 
1,2-linked tri- or tetrasaccharides would constitute a large portion of both A and M 
polysaccharide molecules (Bundle et al. 1989).
The s-LPS of Brucella is highly heterogeneous in chemical structure and in 
immunogenicity between biovars and between LPS types (Caroff et al. 1984a, Dubray 
and Limet 1987, Palmer and Douglas 1989). The expression of s-LPS antigenic 
determinants in the heat-killed B. suis 3 vaccine and in the acetone-killed whole-cell 
preparations of B. melitensis and B. abortus could vary markedly. This is especially true 
where chemical or heat processing may have altered antigen structure. Many different 
types of antigenic determinants, other than those containing A and M-specific epitopes,
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could be exposed in these whole-cell preparations. This could account for the high 
degree of antibody binding on B. melitensis seen with sera of vaccinated reindeer.
Improperly blocked epitopes common to both A and M polysaccharides could 
provide binding sites for antibody in sera of B. suis 3-vaccinated reindeer. As noted 
previously, common epitopes could constitute a large portion of the O polysaccharide 
molecule (Bundle et al. 1989). These may not have been sufficiently blocked by the 
monoclonal antibody C-l.
C-l has been characterized as a monoclonal antibody that binds epitopes common 
to both A and M-sLPS, which are not present in Yersinia enterocolitica 0:9 
O polysaccharide (Palmer and Douglas 1989). The O polysaccharide chains of 
enterocolitica 0:9 and B. abortus are identical (Bundle et al. 1984, Caroff et al. 1984a). 
This evidence suggests that C-l may be specific for core components of s-LPS, rather 
than O polysaccharide components. C-l therefore would not block O polysaccharide 
epitopes common to both A and M antigens in whole-cell preparations of Brucella. The 
presence of exposed common epitopes on B. melitensis polysaccharide could account for 
binding of antibodies from vaccinated reindeer.
The addition or substitution of additional monoclonal antibodies against common 
determinants of A and M antigens would likely improve ELISA discrimination of 
vaccinated and infected reindeer if common epitopes had not been sufficiently blocked.
A combination of monoclonal antibodies may provide a better block of common A and 
M epitopes than a single antibody. Hewitt et al. (1982) increased the sensitivity of a 
competitive ELISA for the detection of tuberculosis in humans by the use of 2 or more 
inhibitive monoclonal antibodies. A combination of monoclonal antibodies with defined 
specificities (Douglas and Palmer 1988, Bundle et al. 1989) therefore may be needed to 
adequately block common determinants on the s-LPS molecule.
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There is another explanation for the high level of antibody to B. melitensis 
antigens in sera of vaccinated reindeer. Perhaps antigens unrelated to O polysaccharide 
were exposed in the whole-cell antigen preparation. Lesser antigenic determinants such 
as outer-membrane lipids or proteins could provide binding sites for reindeer antibody 
regardless of the presence or absence of A and M antigens. This would result in 
"background" antibody binding on both types of whole-cell antigen. This "background" 
would be expected to gradually increase with time after exposure to B. suis.
This explanation is unlikely for two reasons. First, s-LPS-specific antibody 
interaction with s-LPS antigen probably obscures lesser antigenic determinants in whole­
cell preparations (Nielsen and Wright 1984, Cloeckaert et al. 1990). Second, it is 
unlikely that sufficient antibodies specific for antigens other than s-LPS would be 
produced by vaccinated reindeer to account for high M antigen OD readings. Although 
antibodies are produced against antigens that are distinct from the s-LPS complex 
(Schurig et al. 1978), the primary antibody response of animals exposed to smooth 
Brucella species is directed against s-LPS (Diaz et al. 1968, Schurig et al. 1981,1984, 
Moreno etal. 1987).
Discrimination between vaccinated and infected reindeer on the basis of the 
antibody response to the M antigen was not feasible. Nonetheless, discrimination was 
possible when the M-specific antibody level of vaccinated reindeer was assessed as a 
proportion of total antibody as detected by the A antigen-based ELISA. A percentage 
difference variable correctly classified 89% of 117 reindeer as either B. suis 4-infected or 
B. suis 3-vaccinated. The percentage difference was specific in discriminating between 
vaccinated and infected reindeer, false-positives totalled 8%. Nonetheless, the sensitivity 
was only moderate, with 80% of infected reindeer correctly identified. The ELISA
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would be suitable for assessing the overall prevalence of brucellosis in herds of B. suis 3- 
vaccinated reindeer.
This test of discrimination, however, is not sensitive enough to apply to reindeer 
on an individual basis. The ability to identify infected individual reindeer in vaccinated 
herds is important for culling purposes and in selecting reindeer for shipment to Brucella- 
free areas. Ideally, a discriminatory test would identify 100% of infected animals. 
Unfortunately, ELISA criteria for classifying reindeer as "infected" cannot be established 
where all infected reindeer are included, without also including an unacceptably large 
proportion of negative, vaccinated reindeer. In addition, reindeer that have been recently 
infected (within a month or two of sampling) can not be differentiated from vaccinated 
reindeer.
Antibody Responses to A and M Antigens as Measured Over Time
ELISA results from reindeer sampled sequentially after exposure to B. suis 
showed that the antibody response to the A antigen predominated immediately after that 
event. In vaccinated reindeer, this was followed by a gradual increase in antibody to the 
M antigen, as detected in the ELISA. This increase occurred within the first 7 months 
after vaccination. Subsequently, an equilibrium was established where the antibody 
response to the M antigen was approximately 70-80% of the A-antibody response. 
Equilibrium was attained before antibody titers started to decline. The ELISA detection 
of antibodies specific for M antigen probably was not selective enough to exclude 
antibodies specific for determinants common to both A and M polysaccharide antigens. 
This would account for the gradual increase in measured M-antibody response in 
vaccinated reindeer.
The 5. melitensis antigens responsible for the production of nonspecific 
agglutinins are likely to have been associated with the 0  polysaccharide molecule. This
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suggestion is in accordance with those of Jones (1958), who sequentially bled rabbits up 
to 53 days after infection with B. melitensis to determine optimum-sampling time for the 
production of monospecific serum. M-Specific agglutinins (antibodies) predominated 6 
days after inoculation. As time elapsed, the proportion of nonspecific, heterologous 
agglutinins in the sera increased. More recent research has shown that the 
O polysaccharide component of s-LPS is primarily responsible for the production of 
agglutinating antibodies (Diaz et al. 1968, Schurig et al. 1981). An increase in the 
production of common determinant-specific antibodies relative to the production of M- 
specific antibodies would explain the increase in heterologous agglutinins in rabbit sera 
as measured over time.
The antibody response to the M antigen developed more slowly than the response 
to the A antigen in B. suis 4-infected reindeer. This was unexpected. Recent research 
has indicated that in A+M+ biovars, such as B. suis 4, that A and M epitopes exist 
together on the same molecule rather than on two separate antigenic structures (Bundle et 
al. 1989, Meikle et al. 1989, Garin-Bastuji et al. 1990). Although the chemical structure 
of A and M epitopes has been identified (Bundle et al. 1989), their distribution on 
O polysaccharide chains has not been clarified. The lag in antibody response to the M 
antigen in infected reindeer indicates that M epitopes may occur more frequently on the 
core end or length of the O polysaccharide chain, rather than on the tip. There is, 
however, an alternative explanation. Past theories suggested that A and M antigens are 
separate molecular structures existing in equal proportions on the s-LPS of B. suis 4. 
Under this theory, a differential distribution of A and M common and M-specific 
epitopes along the M polysaccharide chain could account for the lag in antibody response 
to the M antigen in infected reindeer. The initial antibody response of infected reindeer 
may be directed against epitopes common to both A and M antigens, if these existed near
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the tip of the M polysaccharide. Antibodies to determinants containing M-specific 
epitopes would appear later if these existed towards the core end of the O polysaccharide 
chain.
My hypotheses regarding the differential immunogenicity of epitopes as they are 
placed on the O polysaccharide chain are consistent with those proposed by Nielsen et al. 
(1989), and colleagues (Wright et al. 1990). They suggested that epitopes existing along 
the length of the O polysaccharide chain were only weakly immunogenic compared with 
the "tip" epitope. They also suggested that cattle would only produce antibodies to 
"length" epitopes when exposure was prolonged, as in infection.
The M-antibody response lags behind the A response in infected reindeer. The 
serologic response to these antigens, however, becomes equivalent This indicates that 
equal quantities of both A and M epitopes are expressed in the B. suis 4 organism. Garin- 
Bastuji et al. (1990) noted results from latex-particle agglutination inhibition tests that 
suggested B. suis 4 showed a predominance of M antigen. This is contrary to the results 
of others who have reported equal A and M antigen expression in B. suis 4 (Dubray and 
Limet 1987, Douglas and Palmer 1988, Meikle et al. 1989, Palmer and Douglas 1989).
I documented that the ELISA will be a useful test in the diagnosis of brucellosis 
in reindeer. The ELISA is more sensitive than agglutination tests currently employed, 
and therefore will provide additional information used in adjunct to these tests. ELISA 
discrimination between B. suis 3-vaccinated reindeer andfi. suis 4-infected reindeer is 
sufficient to allow assessment of the prevalence of brucellosis in vaccinated herds, but is 
not sufficient to identify infected individuals.
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CHAPTER 3.
EFFICACY OF A KILLED BRUCELLA SUIS BIOVAR 3 VACCINE IN 
REINDEER CHALLENGE EXPOSED WITH BRUCELLA SUIS BIOVAR 4.
ABSTRACT
Seven female reindeer were vaccinated with killed Brucella suis biovar 3 vaccine. 
This group consisted of 5 pregnant adults and 2 8-month-old calves. These reindeer were 
challenged with 3.155 x 10^ colony forming units of Brucella suis biovar 4 at 63 days 
post-vaccination. Five pregnant adults and 1 female calf served as experimental controls. 
B. suis 4 was isolated from 3 of 7 vaccinated reindeer (43%) at the time of necropsy.
B. suis 4 was isolated from the aborted fetus of 1 of the infected vaccinates. Another 
infected vaccinate bore a healthy calf that was negative for B. suis 4 at necropsy. All 
control reindeer were infected and all 5 adults aborted. B. suis 4 was isolated from all 5 
fetuses. The B. suis 3 vaccine provided significant protection against infection and 
abortion in reindeer challenged with B. suis.
INTRODUCTION
Brucellosis caused by Brucella suis biovar 4 is enzootic in Alaskan reindeer herds 
(Meyer 1966, Dieterich 1981). The main effect of the disease is on loss of productivity 
through abortion. Additionally, the disease causes orchids, epidymitis and sterility in 
males (Golosov and Zabrodin 1959), and arthritis and bursitis with accompanying 
lameness in both sexes (Orloff 1963).
64
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The serologic prevalence of brucellosis in certain reindeer herds in Alaska maybe 
as high as 20% (Dieterich 1981). A killed B. suis 4 vaccine (Dieterich et al. unpubl.) is 
currently used to control brucellosis in approximately 80% of Alaskan reindeer herds.
Serologic diagnosis of brucellosis in vaccinated reindeer is unfeasible. There are 
no detectable qualitative or quantitative differences in the antibody responses between 
vaccinated and naturally infected reindeer. My objective was to produce a vaccine that 
would allow serologic discrimination between vaccinated and infected reindeer. A killed 
Brucella suis strain 636 (biovar 3) was chosen as a vaccine. This biovar lacks the M 
polysaccharide antigen that is present in B. suis 4 (Wilson and Miles 1932). Antibodies 
directed against this antigen might be detected by means of a specifically designed 
enzyme-linked immunosorbent assay (ELISA). In this manner, vaccinated reindeer could 
be differentiated from naturally infected animals. I hypothesized that the B. suis 3 
vaccine would engender sufficient immunity in reindeer to protect against challenge with 
virulent B. suis 4.
METHODS
Facilities
Reindeer were housed in special isolation facilities at the University of Alaska 
Fairbanks (UAF) from January 22 to May 25,1989. These facilities met published Bio­
Safety Level 3 requirements (Richardson and Barkley 1988). Five rooms of 10.5 rr? 
held from 2 to 3 reindeer each. The containment area was accessible only through an air­
lock system with "shower-in, shower-out" facilities. An additional air-lock provided 
access for the movement of equipment and supplies. Pass-through autoclaves and kill 
tanks for sewage provided for the removal of infected waste. Reduced air pressure was 
maintained in the facility and air was exhausted through absolute filters. Serologic and 
bacteriologic work was performed in isolation suites. Reindeer were bedded on wood
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shavings that were replaced weekly. A commercial grain and pellet mixture * and water 
were offered ad libitum to reindeer. Experimental protocols for the study were approved 
by an independent animal welfare committee at UAF.
Vaccine Preparation
Brucella suis biovar 3 cells were produced in the following manner. Cells of 
B. suis strain 636 (Deyoe 1967) stored in a lyophilized state were reconstituted and 
inoculated onto a tryptose agar^ plate. Cells grown on the plate were observed for 
colony purity and morphology and inoculated onto slants of potato infusion agar (PIA). 
Samples were incubated for 48-72 h after which they were tested for typical 
characteristics of B. suis 3 (Alton et al. 1975). A second set of PIA slants was inoculated 
and incubated for 24 h. Cultures from these slants were used to inoculate 2 Roux flasks 
containing tryptose agar. The flasks were incubated for 2-3 days after which cells were 
harvested and examined for viability on tryptose agar slants. Cultures from the Roux 
flasks were then used to seed media in a fermentation vessel. The production of cells in 
the fermenter vessel followed the procedure outlined in Alton et al.(1975) for batch 
culture on liquid media. Cells were incubated for 48 h using an initial agitation and 
aeration rate of 300-600 RPM and 6-141/min, respectively, for the first 24 h. In the 
following 24 h, agitation and aeration rates were kept at 600 RPM and 141/min. Cells 
were concentrated by centrifugation at 10,000 x g for 45 min. Viability was examined 
before and after this procedure. Cells were washed in saline, refrigerated overnight, 
resuspended in saline at lOOmg/ml and heat-killed in a water-bath at 65°C for 1 h. Cell 
viability was examined again. Cells were then concentrated for storage by centrifugation 
and resuspended at 250 mg/ml in phosphate buffered saline (PBS).
1 Quality Texture, Fisher Mills Inc., Seattle, WA.
2 Difco Laboratories Inc., Detroit, MI.
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Cells of B. suis 3 then were emulsified in Freund's incomplete adjuvant (FIA)^. 
Twelve milliliters of cell concentrate were mixed with 388 ml of PBS. This suspension 
was emulsified in 200 ml of FIA in a blender vessel. The prepared vaccine contained 10 
mg of cells per 2 cc vaccine dose. Vaccine was decanted into sterile multidose vials. All 
vaccine vials were examined for contaminants by culture on blook agar.
Experimental Procedure
Ten mature female reindeer and three 8-month-old female reindeer calves were 
brought into isolation facilities mid-January 1989. Mature reindeer had been with males 
during the previous September and October and were judged to be pregnant via a 
progesterone assay^ (McEwan and Whitehead 1980, Ringberg and Aakvaag 1982) 
conducted in November. All calves were categorized as nonpregnant by this same assay.
There was no serologic evidence of B. suis exposure in any of these reindeer as 
determined by the standard plate (SP), Rivanol (Riv), buffered Brucella antigen 
(BBA)(U.S. Department of Agriculture not dated, b, c) and indirect ELISA tests (Chapter 
2). B. suis 4 was not isolated from the blood of any reindeer. All reindeer were naive to 
challenge by Brucella organisms because all but one had originated from an isolated herd 
kept in double-fenced pens in a brucellosis-free area of Alaska. There had been no 
introductions of reindeer into the herd except for 2 reindeer that had been translocated 
from the Seward Peninsula 4 years previously. There was no serologic evidence of B. 
suis exposure in these 2 animals at the time of their introduction into the herd or any time 
thereafter.
Five adult female reindeer and 2 female calves were vaccinated sub-cutaneously 
in the right mid-cervical area with 2 ml of vaccine on 23 November 1988. Calves were
3 Lee Laboratories, Inc. 1475 Highway 78, S.W., Grayson, GA 30221.
4 Veterinary Reference Laboratories, 411 N.E. 122nd Ave., Suite 140, Portland, OR 
97230
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approximately 8 months-of-age at the time of vaccination. Blood samples for serologic 
testing were taken every 2 weeks until mid-January at which time the reindeer were 
brought into isolation facilities. On 1 January 1989, these reindeer were challenged with 
3.16 x 10? colony-forming units of B. suis biovar 4 instilled in the conjunctival sac. Six 
unvaccinated reindeer consisting of 5 pregnant females and 1 female calf were similarly 
challenged. The challenge strain had been isolated from a Seward Peninsula reindeer and 
had been passaged through lemmings (Lemmus sibiricus) to assure virulence. This 
challenge procedure had been utilized in previous experiments (Dieterich et al. 1980, 
1981, unpubl., Dieterich and Morton 1987) and did not produce overwhelming infections 
in reindeer.
Blood samples were collected weekly for serologic testing and attempted bacterial 
isolation. Lesions of suspect Brucella etiology were cultured. Reindeer were observed at 
12-h intervals after 1 March 1989. Aborted fetuses and calves that died were necropsied 
immediately. Placentas and vaginal swabs were collected from cows immediately after 
parturition or abortion. Vaginal swabs were taken from cows on a weekly basis until 
bacteria were isolated. Milk samples from cows and blood samples from calves were 
collected weekly for bacterial isolation and serology. In late May, approximately 1 
month after calving, reindeer were euthanized and necropsied. Blood and tissue samples 
were collected for bacterial isolation.
B. suis 4 infection in reindeer at necropsy was assessed by the culture of the 
following tissues: right and left prefemoral, popliteal, prescapular, mandibular, parotid, 
suprapharyngeal, retropharyngeal, supramammary, mediastinal, mesenteric, bronchial, 
internal iliac and external iliac lymph nodes, liver, lung, spleen, kidney, muscle, and 
uterus. Aborted fetuses also were necropsied, and stomach contents, spleen, liver, lung, 
and both kidneys were cultured. All tissues were collected aseptically, flamed and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
69
halved. The cut surface was minced with a scalpel. This was then inoculated onto both a 
TSA plate and a more selective media plate containing per liter: 25g tryptose broth, 20g 
of agar^, 0.15ml of Tergitol 7 ,25ml of Tween 40,1.4 mg of ethyl violet, 1.44g of sodium 
lauryl sulfate, 1 vial of CNV^, and 500mg of cylcoheximide^. Vaginal swabs, and swabs 
of milk and stomach contents were similarly inoculated on both media plates. Plates 
were incubated at 37°C and 5% carbon dioxide.
B. suis 4 cultures were identified by colony morphology, gram stain, agglutination 
with positive guinea-pig serum, absence of motility, culture on TSA plates containing the 
inhibitory dyes thionin 1:100,000 and fuschin 1:100,000 and the following biochemical 
tests: Hydrogen sulfide production, catalase and urease production (U.S. Department of 
Agriculture not dated, a).
Serology
All serologic tests were performed the Veterinary Services Laboratory at UAF. 
Standard procedures of the US Department of Agriculture were used for the SP, BBA, 
and Riv tests. An animal was considered positive for serologic tests if: (a) Agglutination 
occurred at a serum dilution of 1:25 on the SP, or (b) Agglutination occurred on the 
BBA, or (c) Incomplete agglutination occurred at a 1:25 dilution on the Rivanol test. 
Serologic tests used for milk were the Brucella ring test (BRT) (U.S. Department of 
Agriculture not dated, b) and whey-plate test (Cameron et al. 1956). The ELISA used 
was an indirect assay developed at the University of Hawaii (Douglas et al. 1984) and 
modified for use in reindeer (Chapter 2). Sera meeting or exceeding minimal titers 
hereafter are referred to as positive; all others are referred to as negative. Polynomial 
regression and curve fitting follow procedures outlined in Chapter 1.
5 Bacto Agar, Difco Laboratories, Detroit, Mich.
6 Cholestimethate, nystatin, vancomycin, Difco Laboratories, Detroit Mich.
7 Actidione, Sigma Chemical Co., St. Louis, MO
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Bacteriology
Bacteremia in reindeer was assessed by weekly blood culture. Five milliliters of 
blood was added to a trypticase soy agar (TSA)^ slant bottle containing 20 ml of tryptose 
broth^ with 1% sodium citrate. Agar slants were incubated at 37°C and 5% carbon 
dioxide for 5 weeks, with inspection for bacterial growth and shaking every 3 days. 
Bacterial growth occurring on slants was transferred to TSA plates for further evaluation. 
This process will be hereafter referred to as hemoculture.
RESULTS
Serology
Reindeer in both vaccinated and unvaccinated groups developed high levels of 
antibody in response to vaccination or infection (Figures 3.1,3.2, and 3.3). All 
vaccinated animals had developed detectable levels of antibody, including positive BBA 
results, within 14 days of vaccination. Detectable levels of antibody were maintained in 
vaccinated reindeer through most of the experiment, with a marked rise in antibody levels 
following challenge with B. suis 4.
All control reindeer exhibited serologic evidence of exposure by 21 days post­
challenge. The SP test was the first to detect a humoral response in control animals.
BBA results were positive in these animals by 14-21 days after challenge, except for 1 
reindeer that was not positive on the BBA until the 35th day after challenge.
Vaccinates and controls were positive on all serologic tests at the time of 
necropsy, except for 1 control reindeer that was negative on the rivanol test.
Agglutination titers were generally lower in the control group of reindeer.
8 Trypticase Soy Agar, Baltimore Biological Laboratories, Cockeysville, Md.
9 Tryptose Broth, Difco Laboratories, Detroit, Mich.
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FIGURE 3.1.
Standard plate test results for 7 reindeer vaccinated with fl. suis 3 vaccine, and 6 non-vaccinated control 
reindeer. Both groups were challenged with virulent fl. suis 4 on day 0. Results are presented as geometric 
mean titers and weighted polynomial regressions.
Y (vaccinates) = 7.151 + 27.51 X - 0.680 X2 + (0.705xl0‘2)X3 - (0.342xl0‘4)X4 + (0.636xl0'7)X5.
r2 = 0.64
Y (controls) = 18785.0 - (9.054xl02)X + 16.62 X2 - 0.145 X3 + (0.613xl0‘3)X4 - (0.100xl0-5)X5.
r2 = 0.94
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FIGURE 3.2.
Rivanol test results for 7 reindeer vaccinated with B. suis 3 vaccine, and 6 non-vaccinated control reindeer. 
Both groups were challenged with virulent B. suis 4 on day 0. Results are presented as geometric mean 
titers and weighted polynomial regressions.
Y (vaccinates) = -2.655 + 10.25 X - 0.292 X2 +(0.402xl0'2)X3 - ( O ^ x lO ^ X 4 + (0.587xl0‘7)X5.
r2 = 0.58
Y (controls) = 75.74 + 3.783 X - 0.220 X2 + (0.321xl0'2)X3 - (0.174xl0-4)X4 + (0.310xl0-?)X5.
r2 = 0.73
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DAYS
FIGURE 33.
ELISA results for 7 reindeer vaccinated with B. suis 3 vaccine, and 6 non-vaccinated control reindeer. Both 
groups were challenged with virulent B. suis 4 on day 0. Results are presented as geometric means of 
spectrophotometric absorbance values with weighted polynomial regressions.
Y (vaccinates) = 0.0598 + (0.5987xl0-1)X - (0.107xl0‘2)X2 + (0.915xl0‘5)X3 - (0.358xI0-7)X4 + 
(0.508xl0'10)X5.
r2 = 0.97
Y (controls) = 41.64 - 1.98 X + 0.0355 X2 - (0.299xi0‘3)X3 + (0.121xl0‘5)X4 - (0.190xl0-8)X5.
r2 = 0.99
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7 4
Four calves were born to vaccinated dams, 3 of these survived following 
parturition. A small amount of poor-quality serum was obtained from the calf that died. 
This serum was negative on the ELISA test. The three remaining calves were 
serologically positive from the day of birth until the time of necropsy. One of these 
calves died within 6 days of birth. The other two lived for 32 and 34 days until they were 
necropsied. These 2 calves were only positive on the ELISA test at the time of necropsy. 
Milk samples taken from postpartum reindeer were positive on the Brucella-ring and 
whey-plate tests.
Bacteriology
Among the 5 adult vaccinates, 1 aborted a fetus in late March from which 
B. suis 4 was isolated. This reindeer retained her placenta for 36 h. The 4 remaining 
pregnant vaccinates bore live calves. B. suis 4 was not isolated from these calves at 
necropsy. One of these calves died shortly after parturition. An empty stomach indicated 
that the calf had never been suckled. Numerous, extensive hemorrhages indicated that 
the calf had died of trauma inflicted by other reindeer. B. suis 4 was isolated from 
vaginal swabs collected up to 1 month postpartum from the vaccinated reindeer that 
aborted. No bacteria were isolated from vaginal swabs from other vaccinates.
Positive hemocultures were obtained from 3 of 7 vaccinated reindeer. Bacteremia 
lasted for 6 weeks in the female that aborted. One positive hemoculture was obtained at 
50 days post-challenge from a pregnant female that did not abort and remained culture 
negative. One other positive hemoculture was obtained from a vaccinated calf that was 
culture-positive at necropsy.
B. suis 4 was isolated from 3 of 7 vaccinated reindeer that aborted. The uterus, 
spleen and 11 lymph nodes were culture-positive in the reindeer that aborted. Another 
vaccinate had a large mammary abscess and 1 mandibular lymph node that were positive
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for B. suis 4. This reindeer had bore a healthy calf and shown no previous signs of 
infection with B. suis 4. In addition, this animal was thin and lacked sub-cutaneous fat. 
B. suis 4 was isolated from 4 head lymph nodes in 1 of the vaccinated calves. Small 
subcutaneous granulomas occurred at the vaccination site in 3 of 7 vaccinates.
All 6 mature nonvaccinated reindeer aborted culture-positive fetuses. Abortions 
occurred from 34 to 74 days after challenge. One of the aborted fetuses was mummified 
(Appendix 1). Placentas were retained for 2 to 3 days post-abortion in 3 of the control 
reindeer. B. suis 4 was isolated from vaginal swabs of all control reindeer from 4 to 6 
weeks post-abortion.
Bacteremia of variable length was seen in all control reindeer. The control 
reindeer with the shortest bacteremia yielded 2 positive hemocultures 3 weeks apart. The 
longest bacteremia was seen in the control calf that showed positive hemocultures for 11 
continuous weeks. Positive hemocultures were obtained in 49% of 82 blood samples 
obtained following challenge.
B. suis 4 was isolated from all control reindeer at necropsy. The most heavily 
infected reindeer (case description in Appendix 1) yielded B. suis 4 from 17 of 30 tissues 
cultured, in addition to 2 peritoneal abscesses. The uterus of this reindeer was filled with 
thick purulent exudate from which B. suis 4 was isolated. Brucella-caused carpal 
arthritis also was observed. Abscesses that were positive for B. suis 4 also occurred in 
one other reindeer. These were associated with the omentum and the wall of the 
omasum. Both reindeer with internal abscesses were thin and lacked sub-cutaneous fat 
reserves.
The vaccine was successful in preventing abortion in 4 of 5 pregnant females, and 
successful in preventing infection in 4 of 7 reindeer (Table 3.1). There was a significant 
difference (P < 0.05) in the infection rate in the vaccinated and control groups using
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TABLE 3.1
Culture results indicating infection and/or abortion in B. suis 3 vaccinated and control 
reindeer challenged with virulent B. suis 4.
RESULTS VACCINATES CONTROLS
Reindeer culture positive
for B. suis 4 at necropsy/ 3/7 6/6
Total reindeer cultured (43%) (100%)
Abortions attributable
to brucellosis/ 1/5 5/5
Total pregnancies (20%) (100%)
Calves culture positive
for fi. suis 4 at necropsy/ 0/4
Total fawns bom (0%)
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Fisher's exact test (Zar 1984). B. suis 4 was isolated from a greater proportion of tissues 
in control reindeer than in vaccinated reindeer (Table 3.2). Bacterial isolations from 
hemocultures were more frequent in the control group than in vaccinated group (Table 
3.3).
DISCUSSION
The killed B. suis 3 vaccine in adjuvant was successful in preventing infection in 
most vaccinated reindeer (4 of 7). I accept the hypothesis that the B. suis 3 vaccine 
engenders sufficient immunity in reindeer to protect against challenge with virulent 
B. suis 4. The challenge inoculum used in this trial appears to have been particularly 
virulent. All 6 control reindeer became infected. Numerous tissues were culture-positive 
in each animal. All 5 pregnant controls aborted fetuses that were positive for B. suis. 
Each control reindeer developed an extended bacteremia. Two of 5 control reindeer 
developed overt clinical disease, with the formation of abscesses and cachesia. Infection 
in control reindeer in experiments and with similar challenge doses has not been as 
severe (Dieterich et al. 1980,1981, unpubl., Dieterich and Morton 1987).
Results from this vaccine test compare favorably with other challenge trials of 
brucellosis vaccines in reindeer and other wildlife species. B. abortus strain 19 did not 
provide protection against infection with B. suis 4 in reindeer (Dieterich and Morton 
1987) or against B. abortus infection in bison (Bison bison) (Davis et al. 1991).
B. abortus strain 19 also caused persistent infections and abortions. Three additional 
vaccines have been tested in reindeer. B. melitensis strain H-38 did not provide 
detectable resistance to B. suis 4 infection (Dieterich et al. 1980). B. abortus strain 45/20 
(Dieterich et al. 1981) protected 5 of 6 vaccinates. A killed B. suis 4 vaccine has
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Numbers of tissues found to be culture-positive for B. suis 4 in control and vaccinated 
reindeer. Where left and right paired samples were cultured, this is indicated by the 
number (2).
TABLE 32
Tissues culture positive Controls Vaccinates
for B. suis biovar 4 (n = 6) (it = 7)
Supramammary lymph nodes (2) 10 2
Mandibular lymph nodes (2) 4 5
Parotid lymph nodes (2) 7 2
Retropharyngeal lymph nodes (2) 3 3
Suprapharyngeal lymph nodes (2) 4 1
Prefemoral lymph nodes (2) 5 0
Uterus 4 1
Abscesses 4 1
Internal iliac lymph nodes 3 1
External iliac lymph nodes 2 1
Prescapular lymph nodes (2) 2 0
Popliteal lymph nodes (2) 0 2
Bronchial lymph nodes 2 0
Udder 2 0
Spleen 1 1
Mediastinal lymph nodes 1 0
Kidneys (2) 1 0
Totals: 55 20
Tissues for which there were no isolations
of B. suis biovar 4:
Liver
Lung
Heart
Muscle
Mesenteric lymph nodes
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TABLE 3.3
Hemocultures positive for B. suis 4 in control and vaccinated reindeer in days subsequent 
to challenge exposure.
Hemocultures positive for B. suis 4 
Days Vaccinates Controls
0 0 0
7 0 0
14 0 4
21 2 5
28 1 6
35 1 2
42 1 4
49 2 6
56 0 3
64 0 4
70 0 2
77 0 2
84 0 1
98 0 0
112 0 0
Totals: 7 39
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provided good protection against infection (Dieterich et al. unpubl.). With this vaccine, 
75%, 86%, 87% and 92% of reindeer were protected against infection when challenged at 
2,14,26 and 43 months post-vaccination, respectively.
The S. suis biovar 3 vaccine also was successful in preventing abortion in 4 of 5 
vaccinated reindeer. One of 2 adult female vaccinates, which became infected following 
challenge, progressed through a normal pregnancy and bore a healthy calf that was 
negative for B. suis. This calf died 6 days after birth. Trauma was the suspected cause of 
death. The dam had a B. suis 4-positive mammary abscess and mandibular lymph node 
on necropsy. Lack of nursing in goats enhances localization and replication of B. abortus 
in mammary glands (Meador et al. 1989). Perhaps the lack of nursing from this reindeer 
contributed towards mammary infection. B. suis 4, however, did not become established 
in the uterus of this reindeer.
Calves have not previously been used in vaccine trials. Russian researchers have 
considered them to be relatively resistant to brucellosis infection because of a general 
absence of lesions and antibody titers (Golosov and Zabrodin 1959, Davidov 1961,
Orloff 1963). The 3 calves used in this study were 8 months-of-age at the time of 
vaccination, and 10 months-of-age at the time of challenge; all were reproductively 
immature. These calves appeared to be as susceptible to brucellosis infection as adults, 
with 2 of the 3 calves becoming infected. No significant difference (P = 0.57) occurred 
in the infection rate of vaccinated adults (2 of 5) and calves (1 of 2) using Fisher's exact 
test, but the power to detect such a difference is low. Whether calves of this age arc able 
to mount an immune response following vaccination similar to that of adults is uncertain. 
Serum antibody levels of the 2 vaccinated calves did not appear to differ from those of 
adult reindeer. Antibody responses of vaccinated adults and calves would be best 
compared using data from a large number of animals sampled sequentially over several
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years. Such data are available from reindeer herds on the Seward Peninsula that have 
been serologically monitored following vaccination with B. suis 4 (Dieterich, pers. 
comm.).
All vaccinated reindeer showed a good antibody response to the vaccine. High 
titers were seen 14 days after vaccination on all serologic tests. Titers in nonvaccinated 
reindeer that became infected were not as high as those in vaccinated reindeer, 
particularly on the Riv test. In bovids, this test detects the IgG j subisotype (Tizard 
1987). Titers in control reindeer were first detected by IgG-specific ELISA and SP tests. 
The latter test primarily detects IgM in standard bovine serology. Titers as measured by 
agglutination tests declined over the course of the trial, whereas ELISA results remained 
stable. Four reindeer maintained high agglutination titers. These included the 2 adult 
vaccinated reindeer that were infected, and also 2 other unvaccinated adults. The ELISA 
was most sensitive in detecting humoral responses to infection and vaccination.
The antibody profiles for the 4 calves that were bom in this trial were as expected. 
The calf that died prior to suckling was serologically negative. The 3 calves that 
survived parturition all showed positive titers. This would be expected with colostral 
intake. The 2 calves that lived for 1 month prior to necropsy had no detectable antibody 
as measured by BBA, SP, and Riv tests. ELISA results were positive at the time of 
necropsy. This is consistent with an expected diminution of passively acquired 
antibodies over time.
Under the conditions of this challenge experiment, the Brucella suis biovar 3 
vaccine induced protection against infection and abortion in reindeer. The duration of 
this immunity beyond 63 days has not yet been determined.
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CONCLUSIONS
Brucellosis caused by B. suis 4 results in serious losses of productivity in reindeer 
herds. The disease presents a hazard to persons associated with the handling or 
butchering of reindeer. Brucellosis in domestic animals is subject to federal regulation. 
Infected reindeer cannot be transported to other states or to brucellosis-free areas of 
Alaska. There is a continuing need to control brucellosis in reindeer by: (1) Improving 
management practices, (2) Optimizing herd immunity through the use of a safe and 
efficacious vaccine, and (3) Improving diagnosis of the disease.
An effective vaccine, based on killed B. suis 4, is currently in use in Alaskan 
reindeer herds. The main disadvantage to the use of this vaccine is that infected reindeer 
in vaccinated herds cannot be distinguished from vaccinated, noninfected animals. This 
has caused difficulties in assessing the prevalences of brucellosis in vaccinated herds, and 
also in the selection of reindeer for export.
The objective of this research was to provide a vaccine for the control of 
brucellosis in reindeer that allows serologic discrimination between vaccinated and 
infected animals. A B. suis 3 vaccine was chosen for this purpose because it possessed a 
different antigenic structure from that of the naturally occurring strain of brucellosis,
B. suis 4.
An enzyme-linked immunosorbent assay (ELISA) was modified for detection of 
reindeer antibodies specific for A and M antigens of B. suis With this test, 89% of 117 
reindeer were correctly classified as either B. suis 3-vaccinated or B. suis 4-infected.
82
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Discrimination between vaccinated and infected reindeer is sufficient to allow assessment 
of brucellosis prevalence in vaccinated herds, but not sufficient to identify infected 
individuals.
The ELISA also will be useful in the diagnosis of reindeer with exposure to B. 
suis. The test was more sensitive than agglutination tests currently employed in the 
diagnosis of brucellosis in reindeer. The ELISA therefore will provide additional 
information when used in adjunct to these tests.
The B. suis 3 vaccine stimulated significant cell-mediated and humoral responses 
in Rangifer. The vaccine provided significant protection against infection and abortion 
following challenge with highly virulent B. suis 4. This vaccine would be suitable for 
further large-scale testing in reindeer. This testing would be necessary prior to general 
application of the B. suis 3 vaccine in Alaskan reindeer herds.
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APPENDIX 1.
FETAL MUMMIFICATION IN A REINDEER (RANGIFER TARANDUS) 
INFECTED WITH BRUCELLA SUIS BIOVAR 4
ABSTRACT
An adult female reindeer (Rangifer tarandus), was challenged with 3.155 x 10^ 
colony forming units of Brucella suis biovar 4. One and one-half months after challenge, 
the reindeer aborted a mummified fetus. Fetal mummification has not been reported 
previously in association with this disease in reindeer. The reindeer also developed a 
generalized, terminal B. suis 4 infection, with rapid development of carpal arthritis, 
abdominal abscesses, bronchopneumonia, and hypergammaglobulinemia.
CASE REPORT
Brucellosis due to Brucella suis biovar 4 infection has been recognized as an 
enzootic disease in reindeer and caribou herds in circumpolar regions (Meyer 1966). The 
main effect of the disease is in reproductive losses from abortions, which occur 1-2 
months before normal calving time (Rausch and Huntley 1978, Zabrodin et al. 1980). 
Abortions are frequently followed by metritis (Zabrodin et al. 1980). Calves of infected 
females normally are weak and later die (Neiland et al. 1968). Surviving calves can 
become carriers of brucellosis (Dieterich 1981). Reindeer that have aborted usually carry 
their calves to term in subsequent years (Nikolaevskii 1961). The disease in males 
frequently is manifested by orchitis and epididymitis (Golosov and Zabrodin 1959). 
Inflammation of the accessory sex organs may occur (Dieterich 1981). B. saw-caused
90
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
91
arthritis and bursitis are common in both sexes (Orloff 1963). In advanced cases, 
abscesses occur in mammary glands, reproductive organs, liver, kidney, peritoneum, and 
subcutaneous tissues (Dieterich 1981). I describe a generalized, terminal B. suis 4 
infection in a reindeer, with the unusual features of fetal mummification, early abscess 
development, bronchopneumonia, and development of hypergammaglobulinemia.
A 6-year old female reindeer, with no serologic evidence of exposure to B. suis 4 
was brought into isolation facilities at the University of Alaska Fairbanks. This animal 
served as a control in a vaccine efficacy experiment. The reindeer was challenged on 25 
January 1989 with 3.155 x 10^ colony forming units of B. suis 4. The inoculum had 
previously been passaged through guinea-pigs and lemmings to assure virulence.
Diarrhea was first noted at 22 days post-inoculation, and lasted 1 week. B. suis 4 
was isolated from blood samples drawn on days 22 and 29. At 40 days post-inoculation, 
recurrence of diarrhea was seen in conjunction with depression and listlessness. A 
greenish, mucoid vulval discharge also was noted. A complete blood count (CBC) and 
fecal analysis revealed a moderate neutrophilia and a heavy strongyle infection. The 
reindeer was treated with ivermectin.
The reindeer aborted a mummified fetus 44 days post-inoculation. Advanced 
autolysis precluded identification of most internal and external features of the fetus. 
Tissue samples identified as heart, lung and liver were cultured on both trypticase soy 
agar* plates and a selective media containing per liter: 25g tryptose broth, 20g of agar^, 
0.15ml of Tergitol 7 ,25ml of Tween 40,1.4 mg of ethyl violet, 1.44g of sodium lauryl 
sulfate, 1 vial of CNV^, and 500mg of cylcoheximide^. Heart and lung yielded almost 
pure cultures of B. suis 4. No bacterial growth was associated with the liver tissue. The
1 Trypticase Soy Agar, Baltimore Biological Laboratories, Cockeysville, Md.
2 Bacto Agar, Difco Laboratories, Detroit, Mich.
3 Cholestimethate, nystatin, vancomycin, Difco Laboratories, Detroit Mich.
4 Actidione, Sigma Chemical Co., St. Louis, MO
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reindeer continued to shed Brucella organisms per vagina until it was euthanized 6 weeks 
later.
Other causes of abortion were ruled out by serologic testing^ of blood samples 
collected prior to challenge, at the time of abortion, and 14 days after abortion. None of 
these samples contained serologic evidence of exposure to infectious bovine 
rhinotracheitis, bovine viral diarrhea, or leptospirosis.
The reindeer regained an alert demeanor after the abortion. Nonetheless, it began 
to lose weight and developed a swollen left carpus 50 days post-inoculation. The carpus 
continued to enlarge until the 78th day post-inoculation, when the synovial membrane 
and skin ruptured and drained a thick purulent exudate. Cultures taken from the carpus 
were positive for B. suis 4. At 85 days post-inoculation, a large prepubic swelling in the 
abdominal body wall was noted, as well as a swelling on the fetlock of the left foreleg. 
The large prepubic swelling was a Brwce//a-positive abscess that broke open at 90 days 
post-inoculation, draining copious amounts of purulent material. The reindeer was 
euthanized at this time for humanitarian reasons because it was cachectic and listless.
On necropsy, generalized pathologic changes related to brucellosis infection were 
evident. The parietal and visceral peritoneum were milky with fibrin deposition. 
Generalized adhesions within the peritoneal cavity bound visceral organs together, with 
numerous attachments to the parietal wall. Four pleural fibrous adhesions were also 
evident The uterus was filled with inspissated suppurative exudate. Two 14-cm 
diameter abdominal abscesses were observed. One was attached to the omentum. The 
other was associated with the body wall just posterior to the umbilicus and had been 
draining to the exterior. The kidneys were pale, enlarged and firm.
5 Washington Animal Disease Diagnostic Laboratory, College of Veterinary Medicine, 
WSU, Pullman, WA 99164.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9 3
Histologic examination of the kidney revealed chronic glomerular nephropathy 
and interstitial nephritis. There was proliferation of the glomerular mesangial cells, 
thickened glomerular basement membranes, marked thickening of Bowman's capsule 
with hypertrophy of the parietal epithelium, and variable glomerular sclerosis. Few 
leucocytes were in glomerular tufts. Several tubules contained hyaline casts, few 
leucocytes, and a few sloughed epithelial cells. Primarily in the cortex but also in the 
medulla, the interstices were expanded by numerous lymphocytes, which multifocally 
effaced renal parenchyma.
In the lung, there was mild to moderate, chronic-active, multifocal 
bronchopneumonia. Lymphocytes and neutrophils were predominantly located in 
peribroncholar interstitium. Small cuffs had formed around bronchi. Additional lesions 
observed histologically were mild multifocal cholangiohepatitis, hepatic and splenic 
hemosiderosis, and lymphocytic depletion in the spleen.
Brucella suis 4 was isolated from 19 of 32 tissues cultured. These included the 
right (R) prefemoral, R prescapular, left (L) mandibular, paired parotid, paired 
suprapharyngeal, R retropharyngeal, paired supramammary, mediastinal, paired internal 
iliac, and external iliac lymph nodes and the spleen, right kidney, uterus, and 2 abscesses.
The serologic response of this reindeer to challenge and infection with B. suis 4 
was delayed compared with other control animals in this and other similar experiments. 
Standard plate (SP), buffered Brucella antigen (BBA) and rivanol (Riv) tests were 
conducted on a weekly basis using standard procedures (U.S. Department of Agriculture 
not dated, b, c). Positive test results were obtained on the BBA at 36 days post­
inoculation, the SP at 22 days post-inoculation, and the Riv at 71 days post-inoculation. 
Antibody titers gradually increased over the course of the infection. Five similarly 
challenged reindeer developed B. snw-specific antibody much more rapidly. All
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serologic test results for these reindeer were positive at day 22 for the BBA, day 14 for 
the SP, and day 36 for the Riv.
Serum samples, which were taken from the subject reindeer pre-challenge and 85 
days post-challenge, were evaluated by serum protein electrophoresis^. Sera from 21 
healthy Seward Peninsula reindeer served as controls. These samples were obtained in 
June. Serum protein electrophoresis has revealed seasonal and age variations in the 
blood proteins of Rangifer (Nieminen et al. 1980, Nieminen and Timisjarvi 1983). 
Results of these tests (Table 4.1, Figure 4.1) show that the subject reindeer developed a 
hypergammaglobulinemia, with gamma 1 globulin levels of 3.62 g/dl, and low serum 
albumin concentrations, with albumin levels of 1.67 g/dl. Albumin/globulin of this 
reindeer was 0.29 as opposed to the mean of 1.57 for healthy reindeer.
Hyperglobulinemia attributable to increased gamma and beta 2 globulin 
concentrations as shown in Figure 4.1 is compatible with increased immunoglobulin 
production. In this case the immunoglobulin increase is likely to be an IgG, IgM 
response associated with persistent antigenic stimulation from B. suis 4. The 
hypoalbuminemia, which accompanies the hyperglobulinemia, may be due to several 
causes. A compensatory decrease in concentration of serum albumin occurs with 
hyperglobulinemia. Also, cachexia associated with chronic inflammation results in 
decreased albumin production, and albumin may have been lost into the urine through 
glomerular lesions.
Necropurulent brucellosis lesions have traditionally been regarded as a chronic 
manifestation of the disease in reindeer, occurring 6 months or more after infection 
(Nikolaevskii 1961, Zabrodin etal. 1980). The subject reindeer developed carpal
6 Veterinary Reference Laboratories, 411 N.E. 122nd Ave., Suite 140, Portland, OR 
97230
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Blood protein electrophoretic values of 21 adult female Seward Peninsula reindeer as 
compared with pre-inoculation and pre-mortem samples taken from case reindeer.
TABLE 4.1.
Reindeer alphal aipha2 betal beta2 gammal gamma2
Seward
Peninsula
Mean 0.22 0.2 0.58 0.55 1.00
Max 0.33 0.29 0.94 0.92 1.27
Min 0.12 0.14 0.16 0.31 0.51
Error 0.04 0.05 0.24 0.25 0.24
Case
Reindeer
pre-inoc 0.37 0.14 0.17 0.60 0.68 1.18
pre-mort 0.38 0.16 0.20 1.36 3.62
Reindeer glob* 2pro-6 alb3 alb/glob
Seward
Peninsula
Mean 2.54 5.60 3.39 1.57
Max 3.75 6.40 3.87 1.86
Min 1.24 4.80 2.81 1.04
Error 0.82 0.54 0.37 0.24
Case
Reindeer
pre-inoc 3.14 6.90 3.75 1.19
pre-mort 5.72 7.40 1.67 0.29
* globulin 
~ protein 
3 albumin
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FIGURE 4.1.
Seram protein electrophoretic values for 21 healthy reindeer and subject reindeer 
expressed as a mean ±  SE for each protein fraction.
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arthritis within 2 months of infection, and a large, draining abscess within 3 months. 
Evidence suggests that in a severe infection or under heavy challenge, the formation of 
brucellosis lesions is expedited. Three reindeer that Davidov (1961) challenged with 
108,109 and 109 5. suis 4 organisms developed necropurulent epididymitis, mastitis, and 
bursitis, respectively, approximately 1 month after challenge. Experience with a 
challenge dose of 10^ CFU of B. suis 4 in other similar experiments suggests that it 
should not be considered a heavy challenge. This dose does not usually cause a severe 
infection in reindeer.
Abortion is a common symptom of brucellosis in reindeer. Fetal mummification 
has not been reported previously. One report (Rausch and Huntley 1978) details the 
abortion of a mascerated fetus under similar circumstances. Bacterial culture of this fetus 
was not attempted. Thus the cause of abortion remains unclear. Fetal mummification 
has been seen in swine and dogs in association with brucellosis infection but has not been 
reported in the literature (Deyoe, pers. comm.).
Bronchopneumonia is a common manifestation of aborted animals infected with 
brucellosis. This finding, however, is unusual in infected adult animals.
Brucellosis in reindeer is considered a disease of high morbidity but low mortality 
(Nikolaevskii 1961, Rausch and Huntley 1978, Zabrodin et al. 1980, Dieterich 1981). I 
believe that the subject reindeer would have died of brucellosis. Perhaps the case fatality 
rate in reindeer herds has been underestimated. Certainly, B. suis-caused arthritis and 
bursitis, and also the lack of vigor associated with severe, generalized infection would 
make reindeer more susceptible to predation. Under herding systems presently used in 
Alaska, the loss of these animals would go unnoticed.
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Also, this case is notable in that this reindeer shed Brucella organisms: (1) In 
vaginal exudate, (2) From an infected joint, and (3) From a draining abscess. This 
drainage persisted over 2 months. Such a reindeer would present a large infection risk 
for other reindeer it was in contact with and would be a major source of ground 
contamination.
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